Biomarkers for lymphoma

ABSTRACT

A biomarker, method, test kit, and diagnostic system for detecting the presence of lymphoma in a person are disclosed. The lymphoma may be Hodgkin&#39;s lymphoma or non-Hodgkin&#39;s lymphoma. The person may be a high-risk subject. In one embodiment, a plasma sample from a person is obtained. The level of at least one protein listed in Table S3 in the plasma sample is measured. The level of at least one protein in the plasma sample is compared with the level in a normal or healthy subject. The lymphoma is diagnosed based upon the level of the at least one protein in the plasma sample in comparison to the normal or healthy level.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional APPLICATION Ser.No. 61/565,036, filed Nov. 30, 2011, titled “BIOMARKERS FOR HODGKIN'SLYMPHOMA”, hereby incorporated by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

The invention was made with Government support under ContractDE-AC05-76RLO1830, awarded by the U.S. Department of Energy. TheGovernment has certain rights in the invention.

TECHNICAL FIELD

This invention relates to biomarkers for lymphoma. More specifically,this invention relates to plasma biomarkers for detecting Hodgkin'slymphoma or non-Hodgkin's lymphoma.

BACKGROUND OF THE INVENTION

In the presence of human immunodeficiency virus (HIV) infection,non-Hodgkin's lymphoma (NHL) and Kaposi sarcoma (KS) were the firstmalignancies used to define acquired immune deficiency syndrome (AIDS).People with HIV infection are also at increased risk of a number ofother cancers. As people with HIV infection live longer due to highlyactive antiretroviral therapy (HAART), the incidence of thesenon-AIDS-defining cancers has increased among HIV-infected individuals.One of the most common of these malignancies is Hodgkin's lymphoma (HL),and it has been estimated that people with HIV/AIDS have a 5.6- to14.7-fold increased risk of developing HL compared to the generalpopulation.

HL is a solid tumor that is comprised of no more than 2% of thecancerous B lymphocytes. Instead, these lymphocytes secrete a wide rangeof cytokines that attract numerous normal leukocytes that then comprisethe large majority of the tumor. Thus, HL is largely seen as anuncontrolled inflammatory disease. In people with immunosuppression, HLis believed to result from the Epstein-Barr virus (EBV). EBV is presentin nearly all adults, but typically only causes HL when the immunesystem is suppressed, such as with HIV infection.

The increase in non-AIDS-defining cancers has created a greater need forthe early detection of these malignancies in this susceptiblepopulation. It seems likely that HIV-infected individuals would benefitfrom a routine, non-invasive screen for HL, but no such screen exists.Rather, HL patients are identified after they become symptomatic.Chemotherapy and radiation therapy have been shown to be very effectiveat causing HL remission, but morbidity and mortality associated withthese treatments is substantial. Early-stage HL is generally treatedless intensively, suggesting that early detection of HL would result inless treatment-related toxicity. Cancer treatment strategies forHIV-infected individuals with HL are the same as for non-AIDS subject,but HIV-infected patients require additional vigorous supportive care(HAART, antifungals, neutrophil-simulating growth factors).

What is needed is a blood-based test to detect lymphoma earlier, whenthe tumor burden is much smaller, which would allow for less severetherapy and reduce long-term mortality and morbidity associated withcurrent treatments.

SUMMARY OF THE INVENTION

In one embodiment of the present invention, a biomarker for detectinglymphoma in a person is disclosed. The biomarkers include at least oneprotein listed in Table S3.

The lymphoma may be Hodgkin's lymphoma or non-Hodgkin's lymphoma. The atleast one protein is found in plasma, and the person is a high-risksubject.

In another embodiment of the present invention, a method of detectinglymphoma in a person is disclosed. The method includes obtaining aplasma sample from the person. The method further includes measuring thelevel of at least one protein listed in Table S3 in the plasma sample.The method also includes comparing the level of the at least one proteinin the plasma sample with the level in a normal or healthy subject; anddiagnosing the lymphoma based upon the level of the at least one proteinin the plasma sample in comparison to the normal level. In oneembodiment, the obtaining a plasma sample from the person furthercomprises providing a reagent that reacts with proteins in the plasmasample to detect the presence of lymphoma. The reagent may be anantibody.

In another embodiment of the present invention, a test kit fordiagnosing lymphoma in a person is disclosed. The test kit includes anantibody-based assay that measures a plurality of plasma biomarkersselected from the group consisting of the biomarkers of Table S3; andinstructions for conducting the antibody-based assay.

In another embodiment of the present invention, a diagnostic system fordetecting the presence of lymphoma in a person is disclosed. The systemincludes a plurality of protein assays measuring a plurality of plasmabiomarkers. The plasma biomarkers are selected from the biomarkers ofTable S3. Concentration levels or peak intensity values of at least oneof the plasma biomarkers is modified by the presence of the lymphoma inthe person. The system also includes a detector for detecting the plasmabiomarkers.

In one embodiment, the detector is a mass spectrometer. In anotherembodiment, the detector includes at least one labeled antibody specificfor a biomarker of Table S3.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to methods, diagnostic systems, kits,and biomarkers for detecting lymphoma in a patient. These biomarkers mayform the basis for a blood-based test for early detection of lymphomaand may be used clinically.

To identify candidate biomarkers for Hodgkin's Lymphoma (HL) detection,plasma samples from HIV-infected patients were analyzed, with or withoutHL, using accurate mass tag and time (AMT) tag proteomics, and therebyidentified a set of 60 proteins. As a group, these proteins areassociated with both cancer and inflammation and therefore are promisingcandidate biomarkers for early detection of HL.

Materials and Methods

Ethics Statement.

The study protocol was approved by the George Washington UniversityMedical Center Institutional Review Board. Written informed consent wasobtained from all study participants. Additional approval from the PNNLInstitutional Review Board, which included a review of the GeorgeWashington University Medical Center IRB approval, was obtained beforesamples were transferred to PNNL.

Human Subjects and Sample Processing.

-   -   Frozen, human plasma samples were provided by the AIDS and        Cancer Specimen Resource (San Francisco, Calif.). The control        subjects (HIV-infected without HL) were chosen to approximately        match the cases (HIV-infected with HL) based on gender and age        (Table 1). In most cases, plasma samples were collected from        HIV-infected subjects with HL that had not received HL        chemotherapy within at least 30 days (n=12). Information on        chemotherapy was unknown for some cases (n=9) and one sample was        known to have been collected within 30 days of chemotherapy. For        all processing and analytical steps, samples were blocked based        on HL status and randomized. The 12 most abundant plasma        proteins were depleted using the Proteome Purify™ 12        immunodepletion resin (R&D Systems), according to the        manufacturer's protocol. The remaining plasma proteins were        precipitated using ice-cold trichloroacetic acid at a final        concentration of 10%, followed by overnight incubation at 4° C.        and centrifugation at 14,000×g for 5 minutes. The pellet was        washed with cold acetone and dried at room temperature for 5        minutes prior to suspension in 25 μL of 100 mM ammonium        bicarbonate, 8 M urea, 2 M thiourea and 5 mM dithiothreitol, and        heating to 60° C. for 30 min. The samples were then diluted        4-fold with 100 mM ammonium bicarbonate and CaCl₂ was added to 1        mM. Methylated, sequencing-grade trypsin (Promega, Madison,        Wis.) was added at a substrate-to-enzyme ratio of 50:1        (mass:mass) and incubated at 37° C. for 15 h. Peptides were then        purified by binding to a 1 mL SPE C₁₈ column (Supelco,        Bellefonte, Pa.) and eluting with 1 mL of methanol. After        concentration in a SpeedVac, the samples were dissolved in 25 mM        ammonium bicarbonate and frozen at −20° C. until analysis.

TABLE 1 Subject characteristics. HIV+ HIV+/HL+ Number 14 22 Gender (M/F)10/4 20/2 Age (min-max) 53.9 ± 5.9^(a) (42-63) 49.2 ± 8.8 (34-66) CD4count^(b) 404 ± 380 203 ± 224 CD4 count < 200^(c) 4 (29%) 12 (55%)HAART^(d) (yes, no, 12, 1, 1 11, 4, 7 unknown) Lymph node NA^(e)  6involvement ^(a)Mean ± standard deviation. ^(b)Units are CD4-positivecell counts per μL blood. ^(c)CD4 counts of less than 200/μL has beenused to define the presence of AIDS in HIV positive subjects.^(d)Indicates current usage of HAART antiretroviral therapy at the timeof the blood draw. “Unknown” indicates that HAART usage at the time ofthe blood draw is unknown. Prior usage is unknown for all subjects.^(e)NA, not applicable.

Liquid Chromatography-Mass Spectrometry.

Peptide samples were analyzed using a custom-built, automated,high-pressure nanocapillary liquid chromatography (HPLC) system coupledon-line to a LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific).The reversed-phase capillary column was prepared by slurry packing 3-μmJupiter C18 bonded particles (Phenomenex, Torrence, Calif.) into a65-cm-long, 75-μm-inner diameter fused silica capillary (PolymicronTechnologies, Phoenix, Ariz.). The mobile phase consisted of 0.2% aceticacid and 0.05% trifluoroacetate in water (A) and 0.1% trifluoroacetatein 90% acetonitrile, 10% water (B). After loading 5 μL (2.5 μg total) ofpeptides onto the column, the mobile phase was held at 100% A for 50min. Exponential gradient elution was performed by increasing the mobilephase composition from 0 to 55% B over 115 min. The HPLC column wascoupled to the mass spectrometer by an in-house manufacturedelectrospray ionization interface. The heated capillary inlettemperature and electrospray voltage were 200° C. and 2.2 kV,respectively. Data were acquired for 100 min, beginning 65 min aftersample injection (15 min into start of buffer B gradient). Orbitrapspectra (AGC 5×10⁵) were collected from 400-2000 m/z at a resolution of100,000.

The mass spectra were analyzed using the AMT tag approach. The peaklists for each analysis were matched against a mass tag databasecontaining 30,573 tryptic peptides that were previously identified fromLC-MS/MS analyses of human plasma. An estimate of the false-positiverate for peptide identifications in our analysis, which was <6%, wasobtained by searching the sequence-reversed database.

Statistics.

There were 76 mass spectrometry runs included in the proteomics data,including at least two analyses for each of the 36 samples. A total of6460 unique peptides were initially identified. The data-analysisprocess first removed peptides for which there were insufficientidentifications to perform a statistical analysis, which reduced thepeptide number to 3814. Next, the peptide abundance measurements werenormalized via regression based on all the peptide signals for that massspectrometer run and then averaged across replicate runs for eachsample. The averaged signal intensities were normalized for each samplebased on the median absolute deviation of the signal intensity for allpeptides identified in each sample. Finally, the data were subjected totwo statistical tests to determine peptides having differentialabundance due to either signal intensities or presence-absence. Anon-parametric Mann-Whitney test was performed using MatLab 2009 tocompare signal intensities. Differences in detection incidence wasdetermined using a modified Chi-square test, called a G-test. Usingeither test, 647 peptides were identified with a p-value of 0.05 orless.

Normalized peptide abundance values were used for protein inference; thepeptide abundance measurements were weighted and combined to calculatethe relative protein abundances in the two groups using RRollup withinDAnTEm. Only proteins represented by two or more unique peptides wereanalyzed. Peptide redundancy was reduced with Protein Prophet and bymanually selecting characterized proteins over predicted or hypotheticalproteins.

Ingenuity Pathway Analysis.

Differentially regulated proteins were analyzed for common biologicalfunctions using Ingenuity Pathway Analysis (IPA; Ingenuity Systems,Mountain View, Calif.) software. To infer significant biologicalfunctions, all proteins that were significantly different between groupsand their corresponding ratiometric values (HL+/HL−; minimum of 1.5-foldchange) were analyzed by IPA. The significance values for biologicalfunction were determined using the right-tailed Fisher's Exact Test.

Results and Discussion

To identify potential circulating biomarkers for HL in a susceptiblepopulation, we used the AMT tag LC-MS approach to compare the plasmaproteomes from 36 HIV-infected patients with or without HL. TheHIV-infected patients without HL served as the control group to identifyprotein changes associated with HL. The relatively high-throughputcharacteristics of this approach enabled duplicate analyses of each ofthe 36 plasma samples, thereby improving data quality. The subjectcharacteristics are described in Table 1. The proteomics analysisidentified 3814 peptides across all of the samples, which correspondedto 629 proteins. Of these 3814 peptides, 647 were significantlydifferent between the two disease states, which corresponded to 152proteins (Tables S1 and S2). Sixty of these proteins met our criteria ofbeing both significantly different between the two groups and having atleast 1.5-fold difference in the normalized signal (Table S3). Thisprotein list included well-known acute-phase inflammatory proteins,including C-reactive protein and serum amyloid proteins. To betteridentify common biological functions within these 60 proteins, IngenuityPathway Analysis (IPA) was utilized. In general, proteins that wereassociated with immune responses and cancer were highly represented inthe list of significantly altered biological functions. Many of theproteins we identified are known to be secreted by white blood cells,such as those that infiltrate HL tumors, or by the liver, an importantcomponent of the reticuloendothelial system (Table S3). Similarly, theuse of IPA to identify common biological functions across the 60proteins identified “inflammatory response” and “cancer” (Table 2),suggesting that these proteins have a biological relationship with HL.Since only 1% to 2% of the mass of an HL tumor is composed of thecancerous lymphocytes, it may be that the proteins we identified did notoriginate from these relatively rare cells. Rather, these proteins maybe the product of a systemic inflammatory response associated with HL ordue to noncancerous leukocytes that form ˜99% of the tumor mass.

TABLE 2 Top BioFunctions and associated proteins, as defined byIngenuity Pathway Analysis. p-value Name range^(a) Associatedproteins^(b) Inflam- 3.0 × 10⁻¹⁰- AHSG, AMBP, APOE, ARHGDIB, B2M, matory1.1 × 10⁻⁰² C4A/C4B, C8A, CD14, CFD, CRP, GSN, LUM, Re- MBL2, MCAM,MASP1, MSN, PPBP, PNP, sponse PTGDS, PVR, SAA1, SEMA7A, TIMP1 Cancer 9.2× 10⁻⁰⁹- AHSG, AMPB, APOC1, APOE, ARHGDIB, 1.1 × 10⁻⁰² AZGP1, B2M,C4A/C4B, CD14, CFD, COL6A3, CRP, CST3, EFEMP1, GSN, IGFBP2, KRT10, MCAM,MASP1, PNP, PTGDS, SAA1, SELENBP1, TIMP1, YWHAG ^(a)The p-values reflectthe range of all the subcategories that the Ingenuity Pathway Analysisincluded under the header of Inflammatory Response or Cancer. That is,these two BioFunctions have 39 or 35 subcategories, respectively, andeach of these subcategories show significant differences, within therange of p-values shown, between the HIV+ (without HL) and HIV+/HL+groups. ^(b)Abbreviations are defined in Table S3.

At least three of the proteins we identified have been previouslyreported to be increased in HL subjects compared to healthy controls,including C-reactive protein, beta-2-microglobulin and lactatedehydrogenase. These prior studies examined HL in the generalpopulation, and did not focus on HIV-positive subjects. In addition,these studies measured these proteins by immunoassay, providinganalytical verification as well. In the current study, the presence ofHIV in the study population could be a confounding factor. For example,the HL subjects appeared to have slightly more advanced cases of HIV, onthe average, as suggested by a trend (p=0.07, t-test) towards lowerCD4-positive cell counts (Table 1), a result which is consistent withslightly more advanced immunosuppression. Even so, since three of theproteins we identified are increased in HL subjects without HIV, itseems clear that the results for these proteins, at least, are notconfounded by differential states of HIV infection. Overall, the presentstudy independently validates three plasma biomarkers for HL andidentifies an additional 57 novel plasma proteins that appear to bepromising candidate biomarkers based on their relationships with cancerand inflammation. These candidate biomarkers remain to be validated inregards to their association with HL.

The present invention has been described in terms of specificembodiments incorporating details to facilitate the understanding of theprinciples of construction and operation of the invention. As such,references herein to specific embodiments and details thereof are notintended to limit the scope of the claims appended hereto. It will beapparent to those skilled in the art that modifications can be made inthe embodiments chosen for illustration without departing from thespirit and scope of the invention.

TABLE S1 Identified significant peptides Ave HL Ave HL Ratio HL positivenegative positive/ GENE (n = (n = HL SYMBOL Protein Reference Peptide22) 14) negative — P25 IPI:IPI00386965.1 FVTKAEEK 0.22 0.21 1.04 —CDNA FLJ33508 IPI:IPI00166374.1 YNDYLITIK 0.23 fis, clone BRAMY2005094A1BG Alpha-1B- IPI:IPI00022895.7 SLPAPWLSMAPVSWITPGLK 0.45 0.59 0.77glycoprotein A2M Alpha-2- IPI:IPI00478003.1 AFQPFFVELTMPYSVIR 7.72 0.3224.32 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 ASVSVLGDILGSAMQN 0.360.61 0.59 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 ATVLNYLPK 7.930.43 18.58 macroglobulin A2M Alpha-2- IPI:IPI00478003.1AVDQSVLLMKPDAELSASS 4.59 macroglobulin VYNLLPEK A2M Alpha-2-IPI:IPI00478003.1 AYAFALAGNQDKR 0.15 macroglobulin A2M Alpha-2-IPI:IPI00478003.1 DMYSFLEDMGLK 6.62 macroglobulin A2M Alpha-2-IPI:IPI00478003.1 DTVIKPLLVEPEGLEK 9.70 macroglobulin A2M Alpha-2-IPI:IPI00478003.1 GGVEDEVTLSAYITIALLEIP 3.16 macroglobulin LTVTHPVVR A2MAlpha-2- IPI:IPI00478003.1 GHFSISIPVK 6.81 macroglobulin A2M Alpha-2-IPI:IPI00478003.1 GPTQEFK 2.20 macroglobulin A2M Alpha-2-IPI:IPI00478003.1 HYDGSYSTFGER 5.25 macroglobulin A2M Alpha-2-IPI:IPI00478003.1 LLIYAVLPTGDVIGDSAK 9.45 0.31 30.49 macroglobulin A2MAlpha-2- IPI:IPI00478003.1 LLLQQVSLPELPGEYSMK 10.03 0.29 34.54macroglobulin A2M Alpha-2- IPI:IPI00478003.1 LPPNVVEESAR 6.87macroglobulin A2M Alpha-2- IPI:IPI00478003.1 QGIPFFGQVR 4.59macroglobulin A2M Alpha-2- IPI:IPI00478003.1 QTVSWAVTPK 8.37macroglobulin A2M Alpha-2- IPI:IPI00478003.1 SDIAPVAR 3.78 1.61 2.35macroglobulin A2M Alpha-2- IPI:IPI00478003.1 SIYKPGQTVK 5.37macroglobulin A2M Alpha-2- IPI:IPI00478003.1 SVSGKPQYMVLVPSLLHTET 12.16macroglobulin A2M Alpha-2- IPI:IPI00478003.1 TGTHGLLVK 8.95macroglobulin A2M Alpha-2- IPI:IPI00478003.1 VIKPLLVEPEGLEK 0.84 0.990.85 macroglobulin A2M Alpha-2- IPI:IPI00478003.1 VSVQLEASPAFLAVPVEK7.90 macroglobulin ACTA1 Actin, alpha IPI:IPI00021428.1 AGFAGDDAPR 13.4720.00 0.67 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1 DLTDYLMK18.97 28.69 0.66 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1DSYVGDEAQSKR 0.79 0.60 1.32 skeletal muscle ACTA1 Actin, alphaIPI:IPI00021428.1 EITALAPSTMK 26.67 40.43 0.66 skeletal muscle ACTA1Actin, alpha IPI:IPI00021428.1 HQGVMVGMGQK 10.17 10.44 0.97 skeletalmuscle ACTA1 Actin, alpha IPI:IPI00021428.1 SYELPDGQVITIGNER 26.79 39.270.68 skeletal muscle ACTA1 Actin, alpha IPI:IPI00021428.1YPIEHGIITNWDDMEKIWHH 0.86 skeletal TFYNELR muscle ACTB Actin,IPI:IPI00021439.1 AGFAGDDAPR 13.47 20.00 0.67 cytoplasmic 1 ACTB Actin,IPI:IPI00021439.1 DLTDYLMK 18.97 28.69 0.66 cytoplasmic 1 ACTB Actin,IPI:IPI00021439.1 DSYVGDEAQSKR 0.79 0.60 1.32 cytoplasmic 1 ACTB Actin,IPI:IPI00021439.1 EITALAPSTMK 26.67 40.43 0.66 cytoplasmic 1 ACTB Actin,IPI:IPI00021439.1 HQGVMVGMGQK 10.17 10.44 0.97 cytoplasmic 1 ACTB Actin,IPI:IPI00021439.1 SYELPDGQVITIGNER 26.79 39.27 0.68 cytoplasmic 1 ACTBActin, IPI:IPI00021439.1 TTGIVMDSGDGVTHTVPIYE 36.07 48.57 0.74cytoplasmic 1 GYALPHAILR ACTN1 Alpha- IPI:IPI00013508.5 LAILGIHNEVSK1.17 0.70 1.68 actinin-1 ACTN1 Alpha- IPI:IPI00013508.5 VGWEQLLTTIAR1.50 1.32 1.13 actinin-1 ADAMTSL2 ADAMTS-like IPI:IPI00644346.2NFNIAGTVVK 0.68 0.55 1.23 protein 2 AGT AngiotensinogenIPI:IPI00032220.3 STLAFNTYVHFQGK 1.61 AGT AngiotensinogenIPI:IPI00032220.3 VGEVLNSIFFELEADER 0.26 AHSG Alpha-2-HS-IPI:IPI00022431.1 FSVVYAK 80.04 123.13 0.65 glycoprotein ALBSerum albumin IPI:IPI00745872.2 AEFAEVSK 3.86 0.16 23.74 ALBSerum albumin IPI:IPI00745872.2 AVMDDFAAFVEK 26.36 ALB Serum albuminIPI:IPI00745872.2 DVFLGMFLYEYAR 6.14 ALB Serum albumin IPI:IPI00745872.2FKDLGEENFK 19.32 ALB Serum albumin IPI:IPI00745872.2 FQNALLVR 18.06 0.09209.25 ALB Serum albumin IPI:IPI00745872.2 KQTALVELVK 6.23 ALBSerum albumin IPI:IPI00745872.2 KYLYEIAR 2.08 2.41 0.86 ALBSerum albumin IPI:IPI00745872.2 LVAASQAALGL 6.02 ALB Serum albuminIPI:IPI00745872.2 LVNEVTEFAK 25.15 ALB Serum albumin IPI:IPI00745872.2LVTDLTK 5.31 ALB Serum albumin IPI:IPI00745872.2 QNCELFEQLGEYK 1.14 ALBSerum albumin IPI:IPI00745872.2 RHPYFYAPELLFFAK 4.53 ALB Serum albuminIPI:IPI00745872.2 TYETTLEK 5.97 ALB Serum albumin IPI:IPI00745872.2VFDEFKPLVEEPQNLIK 19.11 ALB Serum albumin IPI:IPI00745872.2VPQVSTPTLVEVSR 1.26 ALB Serum albumin IPI:IPI00745872.2 YLYEIAR 7.48ALDH3A1 Aldehyde IPI:IPI00296183.7 FMNSGQTCVAPDYILCDPSI 0.46dehydrogenase, QNQIVEKLKK dimeric NADP- preferring AMBP AMBP proteinIPI:IPI00022426.1 AFIQLWAFDAVK 26.03 45.43 0.57 AMBP AMBP proteinIPI:IPI00022426.1 TVAACNLPIVR 2.78 7.69 0.36 Isoform 2 of Ankyrin repeatdomain- containing ANKRD6 protein 6 IPI:IPI00218274.1 KRERLK 0.06 ANPEPAminopeptidase IPI:IPI00221224.6 ALEQALEK 0.21 0.53 0.40 N APOA1Apolipoprotein IPI:IPI00021841.1 AKPALEDLR 40.63 61.64 0.66 A-I APOA1Apolipoprotein IPI:IPI00021841.1 FLSALEEYTK 0.67 0.46 1.46 A-I APOA1Apolipoprotein IPI:IPI00021841.1 LHELQEKLSPLGEEMRDR 0.99 1.38 0.72 A-IAPOA1 Apolipoprotein IPI:IPI00021841.1 QKVEPLR 5.27 4.80 1.10 A-I APOA1Apolipoprotein IPI:IPI00021841.1 QKVEPLRAELQEGAR 4.64 5.86 0.79 A-IAPOA1 Apolipoprotein IPI:IPI00021841.1 VEPLRAELQEGAR 4.87 5.23 0.93 A-IAPOA1 Apolipoprotein IPI:IPI00021841.1 VQPYLDDFQKK 13.44 32.60 0.41 A-IAPOA1 Apolipoprotein IPI:IPI00021841.1 VSFLSALEEYTK 49.59 71.41 0.69 A-IAPOA4 Apolipoprotein IPI:IPI00304273.2 DSEKLKEEIGK 0.17 A-IV APOA4Apolipoprotein IPI:IPI00304273.2 ISASAEELRQR 0.29 0.81 0.35 A-IV APOA4Apolipoprotein IPI:IPI00304273.2 QLTPYAQR 2.50 2.92 0.86 A-IV APOA4Apolipoprotein IPI:IPI00304273.2 RRVEPYGENFNK 0.22 A-IV APOA4Apolipoprotein IPI:IPI00304273.2 VEPYGENFNK 0.48 0.47 1.01 A-IV APOBApolipoprotein IPI:IPI00022229.1 ALYWVNGQVPDGVSK 0.79 0.47 1.69 B-100APOB Apolipoprotein IPI:IPI00022229.1 DKIGVELTGR 5.81 B-100 APOBApolipoprotein IPI:IPI00022229.1 EEEAASGLLTSLKDNVPK 0.38 B-100 APOBApolipoprotein IPI:IPI00022229.1 ENFAGEATLQR 18.65 17.01 1.10 B-100 APOBApolipoprotein IPI:IPI00022229.1 ESVKFSSK 0.14 B-100 APOB ApolipoproteinIPI:IPI00022229.1 HIYAISSAALSASYK 1.39 0.64 2.17 B-100 APOBApolipoprotein IPI:IPI00022229.1 NIQEYLSILTDPDGKGKEK 1.29 6.98 0.19B-100 APOB Apolipoprotein IPI:IPI00022229.1 QIDDIDVR 8.19 10.09 0.81B-100 APOB Apolipoprotein IPI:IPI00022229.1 SKEVPEAR 0.18 0.17 1.07B-100 APOB Apolipoprotein IPI:IPI00022229.1 SKPTVSSSMEFK 0.16 B-100 APOBApolipoprotein IPI:IPI00022229.1 TEHGSEMLFFGNAIEGK 0.13 0.46 0.27 B-100APOB Apolipoprotein IPI:IPI00022229.1 TLQGIPQMIGEVIRK 1.09 0.81 1.35B-100 APOB Apolipoprotein IPI:IPI00022229.1 VLVDHFGYTKDDKHEQDM 0.80 0.312.56 B-100 VNGIMLSVEK APOB Apolipoprotein IPI:IPI00022229.1 VRESDEETQIK0.07 0.19 0.36 B-100 APOB Apolipoprotein IPI:IPI00022229.1 YEVDQQIQVLMDK0.16 B-100 APOB Apolipoprotein IPI:IPI00022229.1 YKNFATSNK 1.22 1.011.20 B-100 APOB Apolipoprotein IPI:IPI00022229.1 YLRTEHGSEMLFFGNAIEGK0.92 B-100 APOC1 Apolipoprotein IPI:IPI00021855.1 EWFSETFQK 3.00 0.1030.94 C-I APOC1 Apolipoprotein IPI:IPI00021855.1 LKEFGNTLEDK 7.68 0.3025.40 C-I APOC1 Apolipoprotein IPI:IPI00021855.1 MREWFSETFQK 3.08 0.388.18 C-I APOC1 Apolipoprotein IPI:IPI00021855.1 TPDVSSALDKLKEFGNTLED1.13 C-I K APOC2 Apolipoprotein IPI:IPI00021856.3 TAAQNLYEK 5.43 2.861.90 C-II APOC3 Apolipoprotein IPI:IPI00021857.1 SEAEDASLLSFMQGYMK 1.02C-III APOE Apolipoprotein E IPI:IPI00021842.1 FWDYLR 3.08 0.96 3.22 APOEApolipoprotein E IPI:IPI00021842.1 GEVQAMLGQSTEELR 8.71 3.56 2.45 APOEApolipoprotein E IPI:IPI00021842.1 LEEQAQQIR 0.55 0.12 4.78 APOEApolipoprotein E IPI:IPI00021842.1 LKSWFEPLVEDMQR 0.77 0.44 1.76 APOEApolipoprotein E IPI:IPI00021842.1 MEEMGSR 0.29 0.11 2.70 APOEApolipoprotein E IPI:IPI00021842.1 QWAGLVEK 2.11 0.77 2.74 APOEApolipoprotein E IPI:IPI00021842.1 RLAVYQAGAR 0.21 APOE Apolipoprotein EIPI:IPI00021842.1 WVQTLSEQVQEELLSSQVT 6.49 2.16 3.01 QELR APOFapolipoprotein F IPI:IPI00299435.3 SGVQQLIQYYQDQK 1.79 APOH Beta-2-IPI:IPI00298828.3 ATVVYQGER 31.67 42.04 0.75 glycoprotein 1 APOH Beta-2-IPI:IPI00298828.3 EHSSLAFWK 27.55 40.14 0.69 glycoprotein 1 APOH Beta-2-IPI:IPI00298828.3 TCPKPDDLPFSTVVPLK 0.34 0.75 0.45 glycoprotein 1 APOL142 kDa protein IPI:IPI00852826.2 NWFLKEFPR 1.00 0.38 2.59 APOMApolipoprotein M IPI:IPI00030739.1 AFLLTPR 2.31 1.34 1.72 APOMApolipoprotein M IPI:IPI00030739.1 FLLYNR 2.37 1.73 1.37 APOMApolipoprotein M IPI:IPI00030739.1 KWIYHLTEGSTDLR 0.24 ARHGDIBRho GDP-dissociation IPI:IPI00003817.3 ETIVLKEGSEYR 4.62 inhibitor 2ARHGDIB Rho GDP-dissociation IPI:IPI00003817.3 TLLGDGPVVTDPK 0.33inhibitor 2 ARNTL Isoform MOP3 of Aryl IPI:IPI00217736.1 EMTGSGRR 0.21hydrocarbon receptor nuclear translocator- like protein 1 ASLArgininosuccinate  IPI:IPI00220267.7 ALLQAQQA 0.39 0.61 0.64 lyase AZGP1alpha-2- IPI:IPI00166729.4 AGEVQEPELR 11.94 16.22 0.74glycoprotein 1, zinc AZGP1 alpha-2- IPI:IPI00166729.4HVEDVPAFQALGSLNDLQF 19.92 31.15 0.64 glycoprotein 1, zinc FR AZGP1alpha-2- IPI:IPI00166729.4 IDVHWTR 15.39 23.89 0.64 glycoprotein 1, zincAZGP1 alpha-2- IPI:IPI00166729.4 YSLTYIYTGLSK 22.15 34.77 0.64glycoprotein 1, zinc B2M Beta-2-microglobulin IPI:IPI00868938.1IEKVEHSDLSFSK 2.38 B2M Beta-2-microglobulin IPI:IPI00868938.1 IQVYSR0.75 3.60 0.21 BCHE Cholinesterase IPI:IPI00025864.5 DNNSIITR 7.68 9.510.81 BCHE Cholinesterase IPI:IPI00025864.5 WNNYMMDWK 0.35 BHMTBetaine--homocysteine  IPI:IPI00004101.4 AGPWTPEAAVEHPEAVR 1.72S-methyltransferase 1 BLVRB Flavin reductase IPI:IPI00783862.2 HDLGHFMLR0.28 BRUNOL4 LYST-interacting  IPI:IPI00386504.1 MAALNMIWAGSRTYDPNLR0.51 protein LIP9 (Fragment) BRWD1 Isoform B of IPI:IPI00250716.1 ASAVAR19.37 Bromodomain and WD repeat-containing  protein 1 BTD biotinidaseIPI:IPI00218413.2 QEALELMNQNLDIYEQQVM 0.33 0.56 0.59 TAAQK C1QAComplement C1q IPI:IPI00022392.1 SLGFCDTTNK 1.32 1.28 1.03subcomponent subunit A C1QB complement component 1, IPI:IPI00477992.1DQTIRFDHVITNMNNNYEPR 0.66 q subcomponent, B chain C1R Complement C1rIPI:IPI00296165.5  YTTEIIK 4.66 6.69 0.70 subcomponent C1R;Complement C1r IPI:IPI00296165.5 EFMSQGNK 0.59 0.85 0.69 C17orf1subcomponent C1RL Complement C1r-like IPI:IPI00009793.3 GSEAINAPGDNPAK0.42 0.43 0.98 protein C1RL Complement C1r-like IPI:IPI00009793.3LGNFPWQAFTSIHGR 0.13 protein C1S Complement C1s IPI:IPI00017696.1EVKVEKPTADAEAYVFTPN 6.25 9.93 0.63 subcomponent MICAGGEKG C1SComplement C1s IPI:IPI00017696.1 IIGGSDADIK 2.17 subcomponent C1SComplement C1s IPI:IPI00017696.1 TNFDNDIALVR 5.26 6.98 0.75 subcomponentC1S Complement C1s IPI:IPI00017696.1 VKNYVDWIMK 0.50 1.73 0.29subcomponent C2 Complement C2 IPI:IPI00303963.1 SSGQWQTPGATR 0.45 0.630.71 (Fragment) C2 Complement C2 IPI:IPI00303963.1 TPWHVTIKPK 0.31(Fragment) C3 Complement C3 IPI:IPI00783987.2 APSTWLTAYVVK 45.19 52.790.86 (Fragment) C3 Complement C3 IPI:IPI00783987.2 DQLTCNKFDLK 0.28 0.490.58 (Fragment) C3 Complement C3 IPI:IPI00783987.2 DSCVGSLVVK 5.38 7.710.70 (Fragment) C3 Complement C3 IPI:IPI00783987.2 EALKLEEK 39.64 49.250.80 (Fragment) C3 Complement C3 IPI:IPI00783987.2 ETKENEGFTVTAEGK 0.120.08 1.55 (Fragment) C3 Complement C3 IPI:IPI00783987.2EYVLPSFEVIVEPTEKFYYIY 7.25 (Fragment) NEK C3 Complement C3IPI:IPI00783987.2 GQGTLSVVTMYHAK 71.12 89.56 0.79 (Fragment) C3Complement C3 IPI:IPI00783987.2 IEGDHGAR 0.31 0.69 0.45 (Fragment) C3Complement C3 IPI:IPI00783987.2 ILLQGTPVAQMTEDAVDAE 6.56 31.38 0.21(Fragment) RLK C3 Complement C3 IPI:IPI00783987.2 PESWLWNVEDLKEPPK 0.14(Fragment) C3 Complement C3 IPI:IPI00783987.2 PPADLSDQVPDTESETR 0.18(Fragment) C3 Complement C3 IPI:IPI00783987.2 PYVIVPLKTGLQEVEVK 0.681.71 0.40 (Fragment) C3 Complement C3 IPI:IPI00783987.2 SGSDEVQVGQQR39.75 46.61 0.85 (Fragment) C3 Complement C3 IPI:IPI00783987.2SINTHPSQKPLSITVR 0.20 (Fragment) C3 Complement C3 IPI:IPI00783987.2VLLDGVQNPR 83.31 104.55 0.80 (Fragment) C3 Complement C3IPI:IPI00783987.2 VVLVSLQSGYLFIQTDK 4.92 5.73 0.86 (Fragment) C4AComplement component IPI:IPI00643525.1 GQIVFMNREPK 11.87 5.23 2.27 4AC4A Complement component IPI:IPI00643525.1 GSGATFSHYYYMILSR 0.52 4A C4AComplement component IPI:IPI00643525.1 HLVPGAPFLLQALVR 15.53 5.25 2.954A C4A Complement component IPI:IPI00643525.1 LGQYASPTAKR 0.17 0.26 0.644A C4A Complement component IPI:IPI00643525.1 LNMGITDLQGLR 72.56 46.191.57 4A C4A Complement component IPI:IPI00643525.1 LVNGQSHISLSK 0.480.55 0.87 4A C4A Complement component IPI:IPI00643525.1 PNMIPDGDFNSYVR0.43 4A C4A Complement component IPI:IPI00643525.1 SMQGGLVGNDETVALTAFV0.40 0.13 3.05 4A TIALHHGLAVFQDEGAEPLK QR C4A Complement componentIPI:IPI00643525.1 SPSVVHLGVPLSVGVQLQD 0.45 0.70 0.64 4A VPR C4AComplement component IPI:IPI00643525.1 TITVMVENSHGLR 0.29 4A C4B C4B1IPI:IPI00418163.3 GQIVFMNREPK 11.87 5.23 2.27 C4B C4B1 IPI:IPI00418163.3GSGATFSHYYYMILSR 0.52 C4B C4B1 IPI:IPI00418163.3 HLVPGAPFLLQALVR 15.535.25 2.95 C4B C4B1 IPI:IPI00418163.3 LGQYASPTAKR 0.17 0.26 0.64 C4B C4B1IPI:IPI00418163.3 LNMGITDLQGLR 72.56 46.19 1.57 C4B C4B1IPI:IPI00418163.3 LQETSNWLLSQQQADGSFQ 30.40 17.38 1.75 DLSPVIHR C4B C4B1IPI:IPI00418163.3 LVNGQSHISLSK 0.48 0.55 0.87 C4B C4B1 IPI:IPI00418163.3PNMIPDGDFNSYVR 0.43 C4B C4B1 IPI:IPI00418163.3 PVAFSVVPTAATAVSLK 1.057.66 0.14 C4B C4B1 IPI:IPI00418163.3 SMQGGLVGNDETVALTAFV 0.40 0.13 3.05TIALHHGLAVFQDEGAEPLK QR C4B C4B1 IPI:IPI00418163.3 SPSVVHLGVPLSVGVQLQD0.45 0.70 0.64 VPR C4B C4B1 IPI:IPI00418163.3 TITVMVENSHGLR 0.29 C4BPAC4b-binding protein  IPI:IPI00021727.1 GVGWSHPLPQCEIVK 0.29 alpha chainC5 Complement C5 IPI:IPI00032291.2 ATLLDIYK 5.86 7.64 0.77 C5Complement C5 IPI:IPI00032291.2 DSLDQLVGGVPVTLNAQTI 3.49 4.51 0.77DVNQETSDLDPSK C5 Complement C5 IPI:IPI00032291.2 EALQIK 0.40 0.45 0.89C5 Complement C5 IPI:IPI00032291.2 ETVLTFIDPEGSEVDMVEEI 8.40 10.50 0.80DHIGIISFPDFK C5 Complement C5 IPI:IPI00032291.2 IDTQDIEASHYR 4.23 6.450.66 C5 Complement C5 IPI:IPI00032291.2 KIEEIAAK 3.68 5.19 0.71 C5Complement C5 IPI:IPI00032291.2 LKEGMLSIMSYR 2.26 3.67 0.62 C5Complement C5 IPI:IPI00032291.2 LQGTLPVEAR 14.02 18.08 0.78 C5Complement C5 IPI:IPI00032291.2 MVETTAYALLTSLNLKDINY 0.47 4.22 0.11VNPVIK C5 Complement C5 IPI:IPI00032291.2 NFEITIK 4.50 6.52 0.69 C5Complement C5 IPI:IPI00032291.2 QLPGGQNPVSYVYLEVVSK 1.15 1.61 0.72 C5Complement C5 IPI:IPI00032291.2 QYLIMGK 2.80 3.67 0.76 C5 Complement C5IPI:IPI00032291.2 TDAPDLPEENQAR 2.67 4.11 0.65 C5 Complement C5IPI:IPI00032291.2 TLLPVSKPEIR 17.92 23.93 0.75 C5 Complement C5IPI:IPI00032291.2 VFQFLEK 10.48 15.04 0.70 C5 Complement C5IPI:IPI00032291.2 VQVKDSLDQLVGGVPVTLN 1.18 AQTIDVNQETSDLDPSK C5Complement C5 IPI:IPI00032291.2 VVPEGVKR 2.62 3.94 0.67 C5 Complement C5IPI:IPI00032291.2 WLSEEQR 3.06 4.30 0.71 C5 Complement C5IPI:IPI00032291.2 YGMWTIK 3.29 4.61 0.71 C5 Complement C5IPI:IPI00032291.2 YNFSFR 3.90 5.57 0.70 C6 Complement component 6IPI:IPI00009920.2 IGESIELTCPK 7.46 6.33 1.18 C6 Complement component 6IPI:IPI00009920.2 LSEKHEGSFIQGAEK 0.56 0.81 0.70 C7 Complement componentIPI:IPI00296608.6 AASGTQNNVLRGEPFIR 0.18 C7 C7 Complement componentIPI:IPI00296608.6 GGGAGFISGLSYLELDNPAG 1.10 1.41 0.78 C7 NK C7Complement component IPI:IPI00296608.6 VLFYVDSEKLK 0.49 0.90 0.55 C7 C8AComplement component IPI:IPI00011252.1 SLLQPNK 6.84 9.99 0.68C8 alpha chain C8A Complement component IPI:IPI00011252.1YNPVVIDFEMQPIHEVLR 1.61 1.47 1.09 C8 alpha chain C8BComplement component IPI:IPI00294395.1 GGASEHITTLAYQELPTADL 2.13 1.761.21 C8 beta chain MQEWGDAVQYNPAIIK C9 Complement componentIPI:IPI00022395.1 KGVELK 0.12 C9 C9 Complement componentIPI:IPI00022395.1 TEHYEEQIEAFK 11.87 9.19 1.29 C9 CA1Carbonic anhydrase 1 IPI:IPI00215983.3 GGPFSDSYR 0.94 CA1Carbonic anhydrase 1 IPI:IPI00215983.3 HDTSLKPISVSYNPATAK 2.31 CAlCarbonic anhydrase 1 IPI:IPI00215983.3 SLLSNVEGDNAVPMQHNNR 2.88 PTQPLKCACNA2D1 Dihydropyridine receptor IPI:IPI00470535.1 TPNKIDLYDVR 1.410.51 2.74 alpha 2 subunit CCDC89 Coiled-coil domain- IPI:IPI00167663.1ERELNGK 10.66 14.27 0.75 containing protein 89 CD14Monocyte differentiation IPI:IPI00029260.2 AFPALTSLDLSDNPGLGER 0.53 0.461.14 antigen CD14 CD14 Monocyte differentiation IPI:IPI00029260.2ATVNPSAPR 0.36 0.21 1.73 antigen CD14 CD14 Monocyte differentiationIPI:IPI00029260.2 FPAIQNLALR 0.37 0.34 1.11 antigen CD14 CD14Monocyte differentiation IPI:IPI00029260.2 ITGTMPPLPLEATGLALSSLR 0.650.29 2.29 antigen CD14 CD14 Monocyte differentiation IPI:IPI00029260.2LTVGAAQVPAQLLVGALR 0.38 0.31 1.25 antigen CD14 CD14Monocyte differentiation IPI:IPI00029260.2 SWLAELQQWLKPGLK 0.33antigen CD14 CDH5 Cadherin-5 IPI:IPI00012792.1 VHDVNDNWPVFTHR 0.52 CDKL1cyclin-dependent kinase- IPI:IPI00023527.5 SDVDQLYLIR 0.37 like 1 CECR1Cat eye syndrome  IPI:IPI00303071.4 WILLEDYRK 0.35 critical region protein 1 CEP110 Centrosomal protein IPI:IPI00376383.2 AELEKER 0.06 0.120.52 110 kDa CES1 Isoform 1 of Liver IPI:IPI00010180.4QEFGWLIPMQLMSYPLSEG 0.66 carboxylesterase 1 QLDQK CFBIsoform 1 of Complement IPI:IPI00019591.1 LEDSVTYHCSR 0.38 0.38 0.98factor B (Fragment) CFB Isoform 1 of Complement IPI:IPI00019591.1LQDEDLGFL 17.49 20.39 0.86 factor B (Fragment) CFBIsoform 1 of Complement IPI:IPI00019591.1 QLNEINYEDHKLK 0.35 2.99 0.12factor B (Fragment) CFD Complement factor D IPI:IPI00165972.3 LYDVLR0.48 preproprotein CFH Isoform 1 of Complement IPI:IPI00029739.5IDVHLVPDR 33.22 40.39 0.82 factor H CFI Complement factor IIPI:IPI00291867.3 IVIEYVDR 7.42 9.34 0.79 CFI Complement factor IIPI:IPI00291867.3 TMFICK 0.50 CFI Complement factor I IPI:IPI00291867.3VANYFDWISYHVGR 0.21 0.36 0.57 CFL1 Cofilin-1 IPI:IPI00012011.6EILVGDVGQTVDDPYATFV 0.21 K CHIT1 Isoform 3 of IPI:IPI00375364.1FTTLVQDLANAFQQEAQTS 3.66 1.77 2.07 Chitotriosidase-1 GK CLEC3BTetranectin IPI:IPI00009028.1 KDVVNTK 0.03 0.08 0.42 CLEC3B TetranectinIPI:IPI00009028.1 LDTLAQEVALLK 3.37 5.17 0.65 CLEC3B TetranectinIPI:IPI00009028.1 MFEELK 0.19 0.23 0.85 CLEC3B TetranectinIPI:IPI00009028.1 SRLDTLAQEVALLK 0.66 1.07 0.61 CNDP1Beta-Ala-His dipeptidase IPI:IPI00064667.4 DGSTIPIAK 0.41 0.27 1.52CNDP1 Beta-Ala-His dipeptidase IPI:IPI00064667.4 HLEDVFSKR 0.16 CNDP1Beta-Ala-His dipeptidase IPI:IPI00064667.4 MFQEIVHK 0.20 CNTN1Isoform 1 of  IPI:IPI00029751.1 YVHKDETMSPSTAFQVK 0.30 Contactin-1COL1A2 Collagen alpha-2(I)  IPI:IPI00304962.3 DYEVDATLK 0.19 0.30 0.63chain COL6A3 alpha 3 type VI  IPI:IPI00022200.2 SDDEVDDPAVELK 0.17 46.320.00 collagen isoform 1 CP Ceruloplasmin IPI:IPI00017601.1EVGPTNADPVCLAK 8.29 11.01 0.75 CP Ceruloplasmin IPI:IPI00017601.1KLISVDTEHSNIYLQNGPDR 9.19 8.60 1.07 CP Ceruloplasmin IPI:IPI00017601.1PDQVDKEDEDFQESNK 0.26 0.44 0.59 CP Ceruloplasmin IPI:IPI00017601.1PVWLGFLGPIIK 0.31 0.37 0.85 CPB2 Isoform 1 of IPI:IPI00329775.7 YSFTIELR0.63 0.34 1.83 Carboxypeptidase B2 CPN1 Carboxypeptidase NIPI:IPI00010295.1 IVQLIQDTR 2.44 3.28 0.74 catalytic chain CPN1Carboxypeptidase N IPI:IPI00010295.1 TASTPTPDDKLFQK 0.38 0.42 0.90catalytic chain CPN2 similar to IPI:IPI00738433.1 AGGSWDLAVQER 0.99 1.290.77 Carboxypeptidase N subunit 2 CPN2 similar to IPI:IPI00738433.1LSNNALSGLPQGVFGK 2.44 3.86 0.63 Carboxypeptidase N subunit 2 CR2Isoform B of Complement IPI:IPI00216985.1 CVIAGQGVAWTK 0.80receptor type 2 CRP C-reactive protein IPI:IPI00022389.1 AFVFPK 7.084.75 1.49 CRP C-reactive protein IPI:IPI00022389.1 APLTKPLK 15.53 5.332.92 CRP C-reactive protein IPI:IPI00022389.1 ESDTSYVSLK 27.67 7.66 3.61CRP C-reactive protein IPI:IPI00022389.1 GYSIFSYATK 23.94 12.45 1.92 CRPC-reactive protein IPI:IPI00022389.1 KAFVFPK 24.11 5.76 4.19 CRPC-reactive protein IPI:IPI00022389.1 QDNEILIFWSK 3.60 3.94 0.91 CRPC-reactive protein IPI:IPI00022389.1 RQDNEILIFWSK 24.62 17.36 1.42 CRPC-reactive protein IPI:IPI00022389.1 YEVQGEVFTKPQLWP 19.78 11.80 1.68CRYZ Quinone oxidoreductase IPI:IPI00000792.1 VFEFGGPEVLK 0.56 CST3Cystatin-C IPI:IPI00032293.1 ASNDMYHSR 0.25 CST3 Cystatin-CIPI:IPI00032293.1 LVGGPMDASVEEEGVRR 1.32 CTSA cathepsin AIPI:IPI00640525.2 YGDSGEQIAGFVK 0.33 CTSB Cathepsin B IPI:IPI00295741.4SGVYQHVTGEMMGGHAIR 1.34 2.07 0.65 CUL4A Isoform 1 of Cullin-4AIPI:IPI00419273.5 RIESLIDR 4.35 6.76 0.64 DKK3 Dickkopf-related IPI:IPI00002714.1 LLDLITWELEPDGALDR 13.43 protein 3 DSTN DestrinIPI:IPI00473014.5 MIYASSK 0.54 0.25 2.21 ECM1 Extracellular matrixIPI:IPI00645849.1 NLPATDPLQR 0.51 0.77 0.67 protein 1 EFEMP1Isoform 1 of EGF- IPI:IPI00029658.1 QTSPVSAMLVLVK 0.15 0.46 0.34containing fibulin-like extracellular matrix  protein 1 ERAP1Isoform 2 of  IPI:IPI00165949.2 DMNEVETQFK 0.18 Endoplasmic reticulum aminopeptidase 1 ERC1 Isoform 2 of ELKS/RAB6- IPI:IPI00171230.6QTLNARDESIKK 0.28 interacting/CAST family member 1 F10Coagulation factor X IPI:IPI00019576.1 APACLPERDWAESTLMTQK 0.62 F10Coagulation factor X IPI:IPI00019576.1 MLEVPYVDR 0.57 1.48 0.39 F11Isoform 1 of  IPI:IPI00008556.1 ERPGVYTNVVEYVDWILEK 0.14 Coagulationfactor XI F11 Isoform 1 of  IPI:IPI00008556.1 MAESGYDIALLK 0.21 0.450.48 Coagulation factor XI F2 Prothrombin (Fragment) IPI:IPI00019568.1GQPSVLQVVNLPIVERPVCK 0.42 0.68 0.62 F2 Prothrombin (Fragment)IPI:IPI00019568.1 IVEGSDAEIGMSPWQVMLF 12.26 18.80 0.65 R F2Prothrombin (Fragment) IPI:IPI00019568.1 SGIECQLWR 0.24 0.57 0.42 F2Prothrombin (Fragment) IPI:IPI00019568.1 SLEDKTERELLESYIDGR 3.18 F2Prothrombin (Fragment) IPI:IPI00019568.1 TATSEYQTFFNPR 25.22 36.62 0.69F2 Prothrombin (Fragment) IPI:IPI00019568.1 VIDQFGE 19.63 27.80 0.71 F5Coagulation factor V IPI:IPI00022937.4 ASEFLGYWEPR 0.10 FAM71AProtein FAM71A IPI:IPI00217863.2 YAPIFESDFIQITK 0.39 0.35 1.12 FBXO32F-box only protein 32  IPI:IPI00056487.1 LDFSTAILDSR 0.16 FCGBPIgGFc-binding protein IPI:IPI00242956.4 LLFDGDAHLLMSIPSPFR 0.21 FCGR3ALow affinity IPI:IPI00218834.9 AVVFLEPQWYR 0.41 immunoglobulin gamma Fcregion receptor III-A FCN3 Isoform 1 of Ficolin-3 IPI:IPI00293925.2FSEGTAGDSLSLHSGR 0.13 FGA Isoform 1 of Fibrinogen IPI:IPI00021885.1MELERPGGNEITR 14.64 0.77 19.07 alpha chain FGA Isoform 1 of FibrinogenIPI:IPI00021885.1 MELERPGGNEITR 0.46 0.14 3.35 alpha chain FGAIsoform 1 of Fibrinogen IPI:IPI00021885.1 NPSSAGSWNSGSSGPGSTG 2.82alpha chain NR FGA Isoform 1 of Fibrinogen IPI:IPI00021885.1 SRIEVLKR0.30 alpha chain FGB Fibrinogen beta chain IPI:IPI00298497.3MGPTELLIEMEDWKGDK 0.40 FGG Gamma-B of Fibrinogen IPI:IPI00021891.5HLISTQSAIPYALR 0.19 gamma chain FGG Gamma-B of FibrinogenIPI:IPI00021891.5 HLSPTGTTEFWLGNEK 0.22 gamma chain FGGGamma-B of Fibrinogen IPI:IPI00021891.5 KMLEEIMK 0.37 gamma chain FGGGamma-B of Fibrinogen IPI:IPI00021891.5 MIDAATLK 1.23 gamma chain FGGGamma-B of Fibrinogen IPI:IPI00021891.5 MIDAATLK 2.25 0.76 2.97gamma chain FLJ22662 hypothetical protein IPI:IPI00016255.4 KDPYSR 0.33LOC79887 FLJ45139 CDNA FLJ45139 fis,  IPI:IPI00418931.1 TVSIPR 62.5677.85 0.80 clone BRAWH3039623 FLNA filamin A, alpha  IPI:IPI00302592.2AFGPGLQGGSAGSPAR 1.81 1.08 1.67 isoform 1 FLNA filamin A, alpha IPI:IPI00302592.2 AYGPGIEPTGNMVK 3.41 0.56 6.13 isoform 1 FLNAfilamin A, alpha  IPI:IPI00302592.2 GKLDVQFSGLTK 0.80 0.40 1.98isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 IANLQTDLSDGLR 2.051.14 1.80 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 IQQNTFTR0.72 0.56 1.30 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2LIALLEVLSQK 1.88 1.57 1.20 isoform 1 FLNA filamin A, alpha IPI:IPI00302592.2 LPQLPITNFSR 2.00 1.55 1.29 isoform 1 FLNAfilamin A, alpha  IPI:IPI00302592.2 TGVAVNKPAEFTVDAK 1.17 0.45 2.57isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2 VDVGKDQEFTVK 0.830.46 1.80 isoform 1 FLNA filamin A, alpha  IPI:IPI00302592.2VTAQGPGLEPSGNIANK 2.24 1.02 2.20 isoform 1 FLNA filamin A, alpha IPI:IPI00302592.2 VTVLFAGQHIAK 0.95 0.65 1.46 isoform 1 FLNBIsoform 1 of Filamin-B IPI:IPI00289334.1 IQQNTFTR 0.72 0.56 1.30 FLNBIsoform 1 of Filamin-B IPI:IPI00289334.1 LIALLEVLSQK 1.88 1.57 1.20 FN1Isoform 1 of  IPI:IPI00022418.1 GATYNIIVEALK 0.41 Fibronectin FN1Isoform 1 of  IPI:IPI00022418.1 ITGYIIK 0.58 Fibronectin FN1Isoform 1 of  IPI:IPI00022418.1 SYTITGLQPGTDYK 0.38 Fibronectin FN1Isoform 1 of  IPI:IPI00022418.1 VGDTYERPK 0.13 Fibronectin FN1Isoform 1 of  IPI:IPI00022418.1 VTWAPPPSIDLTNFLVR 0.49 Fibronectin FN1Isoform 1 of  IPI:IPI00022418.1 YEKPGSPPR 0.21 0.04 5.18 Fibronectin FTLFerritin light chain IPI:IPI00738499.2 LGGPEAGLGEYLFER 2.66 GAPDHGlyceraldehyde-3- IPI:IPI00219018.7 GALQNIIPASTGAAK 2.28 1.61 1.42phosphate dehydrogenase GAPDH Glyceraldehyde-3- IPI:IPI00219018.7VDIVAINDPFIDLNYMVYMF 0.81 1.39 0.58 phosphate dehydrogenase QYDSTHGKGAPDH Glyceraldehyde-3- IPI:IPI00219018.7 VVDLMAHMASKE 1.18 0.57 2.08phosphate dehydrogenase GC Vitamin D-binding  IPI:IPI00555812.4DKYTFELSR 0.63 0.17 3.70 protein GC Vitamin D-binding  IPI:IPI00555812.4ELSSFIDK 15.57 10.11 1.54 protein GC Vitamin D-binding IPI:IPI00555812.4 SINSPPLYCDSEIDAELKNIL 0.13 protein GGH Gamma-glutamylIPI:IPI00023728.1 MFQNFPTELLLSLAVEPLTA 0.18 hydrolase NFHK GGHGamma-glutamyl IPI:IPI00023728.1 TAFYLAEFFVNEAR 0.20 hydrolase GLRXGlutaredoxin-1 IPI:IPI00219025.3 LKQIGALQ 85.27 121.89 0.70 GOLGA4Isoform 1 of Golgin IPI:IPI00013272.1 EFNTQLAQKE 0.20subfamily A member 4 GP1BA platelet glycoprotein  IPI:IPI00748955.2LTSLPLGALR 0.87 0.91 0.95 Ib alpha polypeptide GP1BAplatelet glycoprotein  IPI:IPI00748955.2 TLPPGLLTPTPK 0.46 0.30 1.56Ib alpha polypeptide GPLD1 Isoform 1 of IPI:IPI00299503.2FGGVLHLSDLDDDGLDEIIM 0.22 0.56 0.40 Phosphatidylinositol- AAPLRglycan-specific phospholipase D GPLD1 Isoform 1 of IPI:IPI00299503.2ILEGFQPSGR 0.32 0.57 0.56 Phosphatidylinositol- glycan-specificphospholipase D GPT Alanine amino- IPI:IPI00217458.3 LLVAGEGHTR 0.11transferase 1 GRM5 glutamate receptor, IPI:IPI00789949.1 KRDQTLMLSFMR0.96 1.62 0.59 metabotropic 5 GSG1L GSG1-like isoform 1IPI:IPI00152159.3 SFIDLAPASEK 0.73 0.58 1.26 GSN GelsolinIPI:IPI00026314.1 AGALNSNDAFVLK 12.54 24.33 0.52 GSN GelsolinIPI:IPI00026314.1 AGKEPGLQIWR 5.68 12.22 0.47 GSN GelsolinIPI:IPI00026314.1 AQPVQVAEGSEPDGFWEAL 2.43 5.88 0.41 GGK GSN GelsolinIPI:IPI00026314.1 AVEVLPK 1.49 2.94 0.51 GSN Gelsolin IPI:IPI00026314.1DSQEEEKTEALTSAK 0.76 1.43 0.54 GSN Gelsolin IPI:IPI00026314.1EGGQTAPASTR 0.23 0.36 0.64 GSN Gelsolin IPI:IPI00026314.1EVQGFESATFLGYFK 5.76 11.95 0.48 GSN Gelsolin IPI:IPI00026314.1GASQAGAPQGR 1.32 2.71 0.49 GSN Gelsolin IPI:IPI00026314.1 GGVASGFK 0.310.61 0.51 GSN Gelsolin IPI:IPI00026314.1 HVVPNEVVVQR 9.30 19.43 0.48 GSNGelsolin IPI:IPI00026314.1 IEGSNKVPVDPATYGQFYG 2.55 4.09 0.63GDSYIILYNYR GSN Gelsolin IPI:IPI00026314.1 MDAHPPR 1.71 3.33 0.51 GSNGelsolin IPI:IPI00026314.1 PALPAGTEDTAKEDAANR 0.16 0.28 0.57 GSNGelsolin IPI:IPI00026314.1 QTQVSVLPEGGETPLFK 9.00 19.74 0.46 GSNGelsolin IPI:IPI00026314.1 RYIETDPANR 0.21 0.37 0.56 GSN GelsolinIPI:IPI00026314.1 TASDFITK 6.07 12.18 0.50 GSN GelsolinIPI:IPI00026314.1 TGAQELLR 8.51 17.56 0.48 GSN GelsolinIPI:IPI00026314.1 TPITVVK 0.66 1.32 0.50 GSN Gelsolin IPI:IPI00026314.1TPSAAYLWVGTGASEAEK 2.75 5.59 0.49 GSN Gelsolin IPI:IPI00026314.1TPSAAYLWVGTGASEAEKT 1.04 3.40 0.31 GAQELLR GSN GelsolinIPI:IPI00026314.1 VPEARPNSMVVEHPEFLK 5.34 12.46 0.43 GSN GelsolinIPI:IPI00026314.1 VPFDAATLHTSTAMAAQHG 7.35 15.87 0.46 MDDDGTGQK GSNGelsolin IPI:IPI00026314.1 YIETDPANR 1.99 4.32 0.46 GULP1Isoform 1 of PTB  IPI:IPI00790010.1 IQDLETENMELK 1.14 domain-containingengulfment adapter protein 1 HBA2;  Hemoglobin subunit IPI:IPI00410714.5 MFLSFPTTK 10.38 26.76 0.39 HBA1 alpha HELLSIsoform 1 of Lymphoid- IPI:IPI00010590.2 NKDSNSIIK 0.17specific helicase HGFAC Hepatocyte growth  IPI:IPI00029193.1 EALVPLVADHK0.41 0.52 0.77 factor activator HOM-TES-1 hypothetical proteinIPI:IPI00022868.3 MKVDMDICR 0.44 0.43 1.04 LOC25900 isoform 4 HPHaptoglobin IPI:IPI00641737.1 HYEGSTVPEK 3.73 1.42 2.62 HP HaptoglobinIPI:IPI00641737.1 LRTEGDGVYTLNDK 10.04 0.37 27.05 HP HaptoglobinIPI:IPI00641737.1 PECEAVCGKPK 0.09 HPR Isoform 1 of  IPI:IPI00477597.1LRTEGDGVYTLNDK 10.04 0.37 27.05 Haptoglobin- related protein HPRIsoform 1 of  IPI:IPI00477597.1 PECEAVCGKPK 0.09 Haptoglobin-related protein HPX Hemopexin IPI:IPI00022488.1 EVGTPHGIILDSVDAAFICPG0.90 1.92 0.47 SSR HPX Hemopexin IPI:IPI00022488.1 VDGALCMEK 3.41 3.810.90 HPX Hemopexin IPI:IPI00022488.1 YYCFQGNQFLR 3.47 5.76 0.60 HRGHistidine-rich  IPI:IPI00022371.1 DVEALDLESPK 0.24 glycoprotein HSPA8Heat shock 70 kDa IPI:IPI00795040.1 DAGTIAGLNVLR 0.33 protein 8 isoform 2 variant (Fragment) HSPA8 Heat shock 70 kDa  IPI:IPI00795040.1NQVAMNPTNTVFDAKR 0.30 protein 8 isoform  2 variant (Fragment) ICAM1Intercellular adhesion IPI:IPI00008494.4 LLGIETPLPK 0.80 molecule 1ICAM1 Intercellular adhesion IPI:IPI00008494.4 VELAPLPSWQPVGK 0.57molecule 1 IGF1 Insulin-like growth  IPI:IPI00001610.1 RLEMYCAPLKPAK0.37 factor IA IGFALS Insulin-like growth  IPI:IPI00020996.3LAYLQPALFSGLAELR 3.49 3.14 1.11 factor-binding  protein complexacid labile chain IGFALS Insulin-like growth  IPI:IPI00020996.3NLIAAVAPGAFLGLK 2.08 2.02 1.03 factor-binding  protein complexacid labile chain IGFBP2 Insulin-like growth  IPI:IPI00297284.1GGKHHLGLEEPK 0.17 factor-binding  protein 2 IGFBP6 Insulin-like growth IPI:IPI00029235.1 HLDSVLQQLQTEVYR 0.28 factor-binding  protein 6 IGHMIGHM protein IPI:IPI00477090.6 LICQATGFSPR 0.25 IGL@ IGL@ proteinIPI:IPI00154742.6 ATLVCLISDFYPGAVTVAW 1.60 0.45 3.58 K IGLV7-43Ig lambda chain V  IPI:IPI00022890.1 FSGSLLGGK 0.38 region 4A ITGA2Bintegrin alpha 2b IPI:IPI00218629.2 NVGSQTLQTFK 0.25 preproprotein ITIH1Inter-alpha-trypsin IPI:IPI00292530.1 DTAVDGVFIR 0.13 inhibitor heavy chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 ELAAQTIKK 8.2114.31 0.57 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 EVAFDLEIPK 28.72 46.70 0.62 inhibitor heavy  chain H1ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 FAHYVVTSQVVNTANEAR 10.9217.76 0.61 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 GHMLENHVER 6.40 11.30 0.57 inhibitor heavy  chain H1ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 GIEILNQVQESLPELSNHASI 3.424.93 0.69 inhibitor heavy  LIMLTDGDPTEGVTDR chain H1 ITIH1Inter-alpha-trypsin IPI:IPI00292530.1 GMADQDGLKPTIDKPSEDSP 27.16 43.870.62 inhibitor heavy  PLEMLGPR chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 GSLVQASEANLQAAQDFVR 15.68 24.71 0.63 inhibitor heavy chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 IADNKQSSFK 0.861.16 0.74 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 ILGDMQPGDYFDLVLFGTR 22.32 47.17 0.47 inhibitor heavy chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 KAAISGENAGLVR 7.5312.44 0.61 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 MSLDYGFVTPLTSMSIR 10.01 17.68 0.57 inhibitor heavy chain H1 ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 MSLDYGFVTPLTSMSIR0.28 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 NHMQYEIVIK 11.50 17.77 0.65 inhibitor heavy  chain H1ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 QAVDTAVDGVFIR 10.25 16.990.60 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 QYYEGSEIVVAGR 2.23 1.21 1.84 inhibitor heavy  chain H1ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 RQAVDTAVDGVFIR 0.50 0.580.86 inhibitor heavy  chain H1 ITIH1 Inter-alpha-trypsinIPI:IPI00292530.1 VTFQLTYEEVLKR 5.67 7.77 0.73 inhibitor heavy  chain H1ITIH1 Inter-alpha-trypsin IPI:IPI00292530.1 VTYDVSR 6.57 10.00 0.66inhibitor heavy  chain H1 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2AIFILNEANNLGLLDPNSVSL 4.89 8.31 0.59 inhibitor heavy  IILVSDGDPTVGELKchain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 DKHADPDFTR 3.355.99 0.56 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsinIPI:IPI00305461.2 ENIQDNISLFSLGMGFDVDY 2.43 4.88 0.50 inhibitor heavy DFLKR chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2FDPAKLDQIESVITATSANT 6.94 12.15 0.57 inhibitor heavy QLVLETLAQMDDLQDFLSK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2FDPAKLDQIESVITATSANT 6.94 12.15 0.57 inhibitor heavy QLVLETLAQMDDLQDFLSK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2FDPAKLDQIESVITATSANT 0.09 inhibitor heavy  QLVLETLAQMDDLQDFLSK chain H2ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 FLHVPDTFEGHFDGVPVISK 42.0567.72 0.62 inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsinIPI:IPI00305461.2 FYNQVSTPLLR 31.04 54.21 0.57 inhibitor heavy  chain H2ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 HADPDFTR 8.05 12.82 0.63inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2IQPSGGTNINEALLR 45.53 79.08 0.58 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 IYGNQDTSSQLK 3.74 4.70 0.80inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2IYGNQDTSSQLKK 8.17 13.87 0.59 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 IYLQPGR 17.11 30.41 0.56inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2KLGSYEHR 3.86 7.12 0.54 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 LDQIESVITATSANTQLVLET 4.61 4.601.00 inhibitor heavy  LAQMDDLQDFLSK chain H2 ITIH2 Inter-alpha-trypsinIPI:IPI00305461.2 LGSYEHR 3.06 4.94 0.62 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 LSNENHGIAQR 10.44 16.74 0.62inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2MATTMIQSK 20.18 33.27 0.61 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 MKQTVEAMK 4.20 7.89 0.53inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2NDLISATK 11.30 17.66 0.64 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 NVKENIQDNISLFSLGMGFD 0.18inhibitor heavy  VDYDFLKR chain H2 ITIH2 Inter-alpha-trypsinIPI:IPI00305461.2 NVQFNYPHTSVTDVTQNNF 6.10 9.78 0.62 inhibitor heavy HNYFGGSEIVVAGK chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2PSGGTNINEALLR 1.96 4.07 0.48 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 SSALDMENFR 29.97 50.84 0.59inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2SSALDMENFR 0.20 0.32 0.62 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 TAGLVR 5.34 9.84 0.54inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2TEVNVLPGAK 29.65 49.53 0.60 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 TILDDLRAEDHFSVIDFNQNI 29.54 49.720.59 inhibitor heavy  R chain H2 ITIH2 Inter-alpha-trypsinIPI:IPI00305461.2 TWRNDLISATK 2.54 4.23 0.60 inhibitor heavy  chain H2ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2 VQFELHYQEVK 10.70 23.59 0.45inhibitor heavy  chain H2 ITIH2 Inter-alpha-trypsin IPI:IPI00305461.2VQSTITSR 15.02 25.32 0.59 inhibitor heavy  chain H2 ITIH2Inter-alpha-trypsin IPI:IPI00305461.2 VVNNSPQPQNVVFDVQIPK 17.70 31.880.56 inhibitor heavy  chain H2 ITIH3 Isoform 1 of Inter-IPI:IPI00028413.8 AREEHRIPER 0.21 0.57 0.36 alpha-trypsin inhibitor heavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8ESPGNVQIVNGYFVHFFAPQ 0.48 0.56 0.86 alpha-trypsin inhibitor  GLPVVPKheavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8MSAQTHGLLGQFFQPFDFK 0.35 alpha-trypsin inhibitor  heavy chain H3 ITIH3Isoform 1 of Inter- IPI:IPI00028413.8 SMEDKGMTNINDGLLR 0.15 0.78 0.19alpha-trypsin inhibitor  heavy chain H3 ITIH3 Isoform 1 of Inter-IPI:IPI00028413.8 TAGLVK 4.87 7.26 0.67 alpha-trypsin inhibitor heavy chain H3 ITIH3 Isoform 1 of Inter- IPI:IPI00028413.8VSDIRPGSDPTKPDATLVVK 0.66 alpha-trypsin inhibitor  heavy chain H3 ITIH4Isoform 1 of Inter- IPI:IPI00294193.4 FAHTVVTSR 35.36 43.76 0.81alpha-trypsin inhibitor  heavy chain H4 ITIH4 Isoform 1 of Inter-IPI:IPI00294193.4 ILDDLSPR 41.07 49.94 0.82 alpha-trypsin inhibitor heavy chain H4 ITIH4 Isoform 1 of Inter- IPI:IPI00294193.4 NVVFVIDK27.71 34.54 0.80 alpha-trypsin inhibitor  heavy chain H4 ITIH4Isoform 1 of Inter- IPI:IPI00294193.4 SAGLVK 5.38 6.71 0.80alpha-trypsin inhibitor  heavy chain H4 KIAA0423 Isoform 1 ofIPI:IPI00744872.2 LHDSNSK 0.23 Uncharacterized protein KIAA0423 KLKB1Plasma kallikrein IPI:IPI00654888.4 YSPGGTPTAIK 2.25 3.35 0.67 KNG1Kininogen-1 IPI:IPI00032328.2 AATGECTATVGKR 0.38 0.72 0.53 KNG1Kininogen-1 IPI:IPI00032328.2 AVDAALKK 18.44 29.10 0.63 KNG1 Kininogen-1IPI:IPI00032328.2 DIPTNSPELEETLTHTITK 47.87 61.90 0.77 KNG1 Kininogen-1IPI:IPI00032328.2 KYFIDFVAR 18.42 24.78 0.74 KNG1 Kininogen-1IPI:IPI00032328.2 QVVAGLNFR 23.86 34.40 0.69 KNG1 Isoform HMW ofIPI:IPI00032328.2 SVSEINPTTQMK 0.20 0.42 0.49 Kininogen-1 KNG1Kininogen-1 IPI:IPI00032328.2 YFIDFVAR 28.85 40.11 0.72 KRT10Keratin, type I  IPI:IPI00009865.2 GSLGGGFSSGGFSGGSFSR 2.13cytoskeletal 10 KRT10 Keratin, type I  IPI:IPI00009865.2SKELTTEIDNNIEQISSYK 3.04 3.69 0.83 cytoskeletal 10 KRT10Keratin, type I  IPI:IPI00009865.2 VTMQNLNDR 1.07 0.19 5.65cytoskeletal 10 KRT2 Keratin, type II  IPI:IPI00021304.1NLDLDSIIAEVKAQYEEIAQ 3.75 cytoskeletal R 2 epidermal KRT2Keratin, type II  IPI:IPI00021304.1 VDLLNQEIEFLK 1.00 cytoskeletal2 epidermal LBP Lipopolysaccharide- IPI:IPI00032311.4 ATAQMLEVMFK 0.88binding protein LBP Lipopolysaccharide- IPI:IPI00032311.4GLQYAAQEGLLALQSELLR 0.36 binding protein LBP Lipopolysaccharide-IPI:IPI00032311.4 ITGFLKPGK 0.61 binding protein LBP Lipopolysaccharide-IPI:IPI00032311.4 ITLPDFTGDLR 1.32 binding protein LBPLipopolysaccharide- IPI:IPI00032311.4 SFRPFVPR 0.59 binding protein LBPLipopolysaccharide- IPI:IPI00032311.4 SPVTLLAAVMSLPEEHNK 0.70binding protein LCP1 Plastin-2 IPI:IPI00010471.5 FSLVGIGGQDLNEGNR 0.43LCP1 Plastin-2 IPI:IPI00010471.5 IKVPVDWNR 0.27 LCP1 Plastin-2IPI:IPI00010471.5 QFVTATDVVR 0.49 LDHB L-lactate   IPI:IPI00219217.3GLTSVINQK 0.47 0.29 1.64 dehydrogenase B chain LDHB L-lactate  IPI:IPI00219217.3 IVADKDYSVTANSK 0.16 0.06 2.44 dehydrogenase B chainLIFR Leukemia inhibitory  IPI:IPI00444272.2 QFLIPPK 409.27 695.10 0.59factor receptor LPA Apolipoprotein IPI:IPI00029168.1 GTLSTTITGR 0.370.36 1.01 LPA Apolipoprotein IPI:IPI00029168.1 GTYSTTVTGR 1.57 5.41 0.29LRG1 Leucine-rich alpha-2- IPI:IPI00022417.4 LGHLDLSGNR 0.25 0.22 1.13glycoprotein LUM Lumican IPI:IPI00020986.2 FNALQYLR 2.01 4.54 0.44 LUMLumican IPI:IPI00020986.2 LKEDAVSAAFK 6.20 12.80 0.48 LUM LumicanIPI:IPI00020986.2 LPSGLPVSLLTLYLDNNK 1.43 3.74 0.38 LUM LumicanIPI:IPI00020986.2 NIPTVNENLENYYLEVNQLE 0.94 2.93 0.32 K LUM LumicanIPI:IPI00020986.2 NNQIDHIDEK 0.22 0.61 0.37 LUM LumicanIPI:IPI00020986.2 SLEDLQLTHNK 6.71 13.68 0.49 LUM LumicanIPI:IPI00020986.2 SLEYLDLSFNQIAR 2.86 6.69 0.43 LUM LumicanIPI:IPI00020986.2 SVPMVPPGIK 2.29 4.55 0.50 MASP1 mannan-binding lectinIPI:IPI00290283.6 TLSDVLQYVK 0.18 0.29 0.64 serine protease 1  isoform 2MBL2 Mannose-binding  IPI:IPI00004373.1 FQASVATPR 4.84 2.46 1.97protein C MCAM Isoform 1 of Cell  IPI:IPI00016334.2 IFLCQGK 2.53 1.501.68 surface glycoprotein MUC18 MED12L Isoform 4 of Mediator IPI:IPI00044353.6 LDPAGSFVPTNTK 0.41 of RNA polymerase IItranscription subunit  12-like protein MEGF8 Isoform 1 of MultipleIPI:IPI00027310.4 SFHAAAYVPAGR 5.16 8.22 0.63 epidermal growth factor-like  domains 8 MMP8 Neutrophil collagenase IPI:IPI00027846.1YYAFDLIAQR 0.45 MSN Moesin IPI:IPI00219365.3 IGFPWSEIR 0.27 MTMR15Isoform 1 of  IPI:IPI00007317.4 RLEPTIK 27.01 34.25 0.79 Coiled-coildomain-containing protein MTMR15 MYCBP2 Putative uncharacterizedIPI:IPI00383833.1 KECEKENK 1.11 protein DKFZp586G0322 (Fragment) NRCAMIsoform 1 of Neuronal  IPI:IPI00333776.5 DSTGTYTCVAR 0.16cell adhesion molecule NRP1 Neuropilin 1 IPI:IPI00398715.5 IKPATWETGISMR0.33 OLFM1 Isoform 1 of Noelin IPI:IPI00017841.2 VSNLEER 1.10 1.90 0.58ORM1 Alpha-l-acid  IPI:IPI00022429.3 YVGGQEHFAHLLILR 2.42 3.78 0.64glycoprotein 1 PCSK9 Isoform 1 of Proprotein IPI:IPI00387168.1VMVTDFENVPEEDGTR 0.67 0.33 2.00 convertase subtilisin/ kexin type 9PCYOX1 Prenylcysteine  IPI:IPI00384280.5 LFLSYDYAVK 0.11 oxidase 1 PDIA3Protein disulfide- IPI:IPI00025252.1 ELSDFISYLQR 0.23 isomerase A3 PDIA3Protein disulfide- IPI:IPI00025252.1 TFSHELSDFGLESTAGEIPVV 0.23isomerase A3 AIR PDIA3 Protein disulfide- IPI:IPI00025252.1 YGVSGYPTLK0.33 0.45 0.72 isomerase A3 PEBP4 PEBP family protein IPI:IPI00163563.3HWLVTDIK 0.37 PFN1 Profilin-1 IPI:IPI00216691.5 DSLLQDGEFSMDLR 1.52 1.281.19 PGLYRP2 N-acetylmuramoyl-L- IPI:IPI00163207.1 AGLLRPDYALLGHR 2.213.02 0.73 alanine amidase PGLYRP2 Isoform 1 of N- IPI:IPI00163207.1EGKEYGVVLAPDGSTVAVE 1.60 3.38 0.47 acetylmuramoyl-L-alaninePLLAGLEAGLQGR amidase PGLYRP2 Isoform 1 of N- IPI:IPI00163207.1RVINLPLDSMAAPWETGDT 0.81 0.86 0.94 acetylmuramoyl-L-alanine FPDVVAIAPDVRamidase PGLYRP2 Isoform 1 of N- IPI:IPI00163207.1 TFTLLDPK 3.40 6.160.55 acetylmuramoyl-L-alanine amidase PGLYRP2 Isoform 1 of N-IPI:IPI00163207.1 WGAAPYR 0.73 0.57 1.27 acetylmuramoyl-L-alanineamidase PI16 Isoform 1 of Peptidase IPI:IPI00301143.5 AQVSPTASDMLHMR0.37 inhibitor 16 PI16 Isoform 1 of Peptidase IPI:IPI00301143.5LMVELHNLYR 0.19 0.68 0.27 inhibitor 16 PLEK Pleckstrin IPI:IPI00306311.8NRQEGLMIASSLLNEGYLQP 0.32 0.53 0.60 AGDMSK PNP Purine nucleosideIPI:IPI00871140.1 VIMDYESLEK 0.16 phosphorylase PODXL Podocalyxin-like IPI:IPI00299116.1 EITIHTK 0.47 0.82 0.57 protein 1 POLR2ADNA-directed RNA IPI:IPI00031627.3 MDDDVFLRCIESNMLTDMT 0.27polymerase II subunit LQGI RPB1 POSTN Isoform 1 of PeriostinIPI:IPI00007960.4 DGHFTLFAPTNEAFEK 3.19 5.78 0.55 PPAN ProteinIPI:IPI00853545.1 RRWSTR 0.17 0.36 0.46 PPBP Platelet basic proteinIPI:IPI00022445.1 DSDLYAELR 0.42 0.19 2.17 PRDX2 Peroxiredoxin-2IPI:IPI00027350.3 IGKPAPDFK 0.64 PRDX2 Peroxiredoxin-2 IPI:IPI00027350.3QITVNDLPVGR 0.47 PROZ Isoform 1 of Vitamin  IPI:IPI00027843.1RAPDLQDLPWQVK 0.21 0.33 0.63 K-dependent protein Z PSAT1 Isoform 1 of IPI:IPI00001734.2 FGTINIVHPK 0.30 Phosphoserine aminotransferase PSMB2Proteasome subunit beta IPI:IPI00028006.1 NGYELSPTAAANFTR 0.15 type-2PTCHD2 Isoform 2 of Patched IPI:IPI00002283.8 ETPPLEDLAANQSEDPRNQR 0.14domain-containing  LSK protein 2 PTGDS Prostaglandin-H2 D-IPI:IPI00013179.1 APEAQVSVQPNFQQDK 5.15 isomerase PVR Isoform Beta of IPI:IPI00219425.3 VLAKPQNTAEVQK 0.09 Poliovirus receptor PZPPregnancy zone protein IPI:IPI00025426.2 AFQPFFVELTMPYSVIR 7.72 0.3224.32 PZP Pregnancy zone protein IPI:IPI00025426.2 ATVLNYLPK 7.93 0.4318.58 PZP Pregnancy zone protein IPI:IPI00025426.2 QGIPFFAQVLLVDGK 0.12PZP Pregnancy zone protein IPI:IPI00025426.2 VVVQTESGGR 0.08 QSOX1Isoform 1 of Sulfhydryl IPI:IPI00003590.2 VLNTEANVVR 0.07 oxidase 1 RBP4Plasma retinol-binding IPI:IPI00022420.3 FSGTWYAMAK 0.59 protein RBP4Plasma retinol-binding IPI:IPI00022420.3 LIVHNGYCDGR 0.29 protein RBP4Plasma retinol-binding IPI:IPI00022420.3 MKYWGVASFLQK 2.10 protein RELNreelin isoform a IPI:IPI00241562.4 TSGITCIKPR 0.67 REREIsoform 1 of Arginine- IPI:IPI00185027.4 KVKEEASSPLK 0.12glutamic acid dipeptide repeats protein SAA1; SAA2 serum amyloid A2IPI:IPI00006146.4 EANYIGSDK 1.45 0.77 1.89 SAA1; SAA2Serum amyloid A protein IPI:IPI00552578.2 EANYIGSDK 1.45 0.77 1.89SAA1; SAA2 serum amyloid A2 IPI:IPI00006146.4 EANYIGSDKYFHAR 2.19 1.221.80 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 EANYIGSDKYFHAR2.19 1.22 1.80 SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2FFGHGAEDSLADQAANEW 4.65 1.07 4.34 GR SAA1; SAA2 serum amyloid A2IPI:IPI00006146.4 FFSFLGEAFDGAR 2.62 SAA1; SAA2 Serum amyloid A proteinIPI:IPI00552578.2 FFSFLGEAFDGAR 2.62 SAA1; SAA2 Serum amyloid A proteinIPI:IPI00552578.2 RGPGGVWAAEAISDAR 4.82 4.49 1.07 SAA1; SAA2serum amyloid A2 IPI:IPI00006146.4 RSFFSFLGEAFDGAR 3.01 2.41 1.25SAA1; SAA2 Serum amyloid A protein IPI:IPI00552578.2 RSFFSFLGEAFDGAR3.01 2.41 1.25 SAA1; SAA2 serum amyloid A2 IPI:IPI00006146.4SFFSFLGEAFDGAR 8.44 6.76 1.25 SAA1; SAA2 Serum amyloid A proteinIPI:IPI00552578.2 SFFSFLGEAFDGAR 8.44 6.76 1.25 SAA1; SAA2Serum amyloid A protein IPI:IPI00552578.2 SGKDPNHFRPAGLPEKY 5.36 SAA4Serum amyloid  IPI:IPI00019399.1 EALQGVGDMGR 11.54 7.35 1.57 A-4 proteinSAA4 Serum amyloid  IPI:IPI00019399.1 VYLQGLIDYYLFGNSSTVLE 0.56 0.192.92 A-4 protein DSK SCML2 Isoform 1 of Sex comb  IPI:IPI00328688.3LDGSDNR 0.32 0.69 0.46 on midleg-like  protein 2 SELENBP1Selenium-binding  IPI:IPI00012303.2 HNVMISTEWAAPNVLR 0.28 0.48 0.58protein 1 SEMA7A Semaphorin-7A IPI:IPI00025257.1 LQDVFLLPDPSGQWR 0.58SEPP1 Selenoprotein P IPI:IPI00029061.2 LPTDSELAPR 1.51 2.10 0.72SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 GKWERPFEVK 56.93 25.112.27 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1GTEAAGAMFLEAIPM 17.00 7.28 2.33 antitrypsin SERPINA1Isoform 1 of Alpha-1- IPI:IPI00553177.1 GTEAAGAMFLEAIPM 0.42 antitrypsinSERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 KLSSWVLLMK 49.95 17.922.79 antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1KLSSWVLLMK 2.15 0.89 2.42 antitrypsin SERPINA1 Isoform 1 of Alpha-1-IPI:IPI00553177.1 KQINDYVEKGTQGK 0.59 antitrypsin SERPINA1Isoform 1 of Alpha-1- IPI:IPI00553177.1 LAEFAFSLYR 12.97 5.48 2.37antitrypsin SERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1LYHSEAFTVNFGDTEEAKK 6.55 antitrypsin QINDYVEK SERPINA1Isoform 1 of Alpha-1- IPI:IPI00553177.1 PFVFLMIEQNTK 0.43 antitrypsinSERPINA1 Isoform 1 of Alpha-1- IPI:IPI00553177.1 TVNFGDTEEAKK 1.01 1.160.86 antitrypsin SERPINA10 Protein Z-dependent IPI:IPI00007199.4NMEVFFPK 0.27 protease inhibitor SERPINA3 Alpha-l-antichymotrypsinIPI:IPI00550991.3 FEEGTEASAATAVK 0.48 SERPINA3 Alpha-l-antichymotrypsinIPI:IPI00550991.3 IIVPTDTQNIFFMSK 1.20 1.08 1.11 SERPINA3Alpha-l-antichymotrypsin IPI:IPI00550991.3 PFDPQDTHQSR 1.66 0.62 2.66SERPINA3 Alpha-l-antichymotrypsin IPI:IPI00550991.3 WVMVPMMSLHHLTIPYFR0.44 SERPINA4 Kallistatin IPI:IPI00328609.3 ATLDVDEAGTEAAAATSFAI 0.470.48 1.00 K SERPINA4 Kallistatin IPI:IPI00328609.3 FYYLIASETPGK 1.571.70 0.93 SERPINA4 Kallistatin IPI:IPI00328609.3 LGFTDLFSK 3.25 5.050.64 SERPINA4 Kallistatin IPI:IPI00328609.3 WADLSGITK 1.79 1.91 0.94SERPINA7 Thyroxine-binding IPI:IPI00292946.1 FAFNLYR 7.38 10.02 0.74globulin SERPINC1 SERPINC1 protein IPI:IPI00844156.2FATTFYQHLADSKNDNDNIF 0.21 LSPLSISTAFAMTK SERPINC1 Antithrombin III IPI:IPI00032179.2 FATTFYQHLADSKNDNDNIF 0.21 variant LSPLSISTAFAMTKSERPINC1 SERPINC1 protein IPI:IPI00844156.2 LVSANR 5.73 8.06 0.71SERPINC1 Antithrombin III  IPI:IPI00032179.2 LVSANR 5.73 8.06 0.71variant SERPINC1 SERPINC1 protein IPI:IPI00844156.2 RVWELSK 36.77 46.370.79 SERPINC1 Antithrombin III  IPI:IPI00032179.2 RVWELSK 36.77 46.370.79 variant SERPINC1 Antithrombin III  IPI:IPI00032179.2VAEGTQVLELPFKGDDITM 0.59 1.01 0.58 variant VLILPKPEK SERPIND1Serpin peptidase  IPI:IPI00292950.4 FAFNLYR 7.38 10.02 0.74 inhibitor,clade D (Heparin  cofactor), member 1 SERPIND1 Serpin peptidase IPI:IPI00292950.4 SVNDLYIQK 9.13 12.01 0.76 inhibitor, clade D (Heparin cofactor), member 1 SERPINF1 Pigment epithelium- IPI:IPI00006114.4LQSLFDSPDFSK 8.16 11.20 0.73 derived factor SERPINF1 Pigment epithelium-IPI:IPI00006114.4 TVQAVLTVPK 5.46 7.34 0.74 derived factor SERPINF1Pigment epithelium- IPI:IPI00006114.4 TVRVPMMSDPK 0.27 0.48 0.57derived factor SERPINF2 Alpha-2-antiplasmin IPI:IPI00879231.1 DFLQSLK0.81 1.36 0.60 SERPINF2 Alpha-2-antiplasmin IPI:IPI00879231.1 GDKLFGPDLK14.71 59.89 0.25 SERPINF2 Alpha-2-antiplasmin IPI:IPI00879231.1IQEFLSGLPEDTVLLLLNAIH 1.79 2.33 0.77 FQGFWR SERPING1 Plasma protease C1IPI:IPI00291866.5 MEPFHFKNSVIKVPMMNSK 0.32 0.62 0.52 inhibitor SERPING1Plasma protease C1 IPI:IPI00291866.5 PVAHFIDQTLK 0.70 inhibitor SERPING1Plasma protease C1 IPI:IPI00291866.5 VATTVISK 0.99 1.68 0.59 inhibitorSH3BGRL2 SH3 domain-binding IPI:IPI00412272.2 ESNTVFSFLGLKPR 0.89glutamic acid-rich-like protein 2 SH3BGRL3 SH3 domain-bindingIPI:IPI00746352.1 VYSTSVTGSR 0.25 0.22 1.14 glutamic acid-rich-likeprotein 3 SHBG Isoform 1 of Sex  IPI:IPI00023019.1 IALGGLLFPASNLR 0.811.62 0.50 hormone-binding  globulin SHBG Isoform 1 of Sex IPI:IPI00023019.1 TSSSFEVR 0.16 0.39 0.42 hormone-binding  globulin SHBGIsoform 1 of Sex  IPI:IPI00023019.1 VVLSSGSGPGLDLPLVLGLP 0.41 0.97 0.42hormone-binding  LQLK globulin SLC14A2 Urea transporter, IPI:IPI00177820.3 ASIITK 0.72 0.95 0.75 kidney SLC9A6 Sodium/hydrogenIPI:IPI00022061.5 LLNLGR 0.43 exchanger 6 SMG7 Breast cancer-associatedIPI:IPI00871896.1 MSFLGILCK 0.16 0.14 1.17 antigen SGA-56M SVILIsoform 2 of  IPI:IPI00018370.3 RSRNTAVEQRLR 0.50 Supervillin TAGLN2Transgelin-2 IPI:IPI00550363.3 DVGRPQPGRENFQNWLK 0.27 TAOK1 Isoform 1 ofIPI:IPI00002232.2 VSLRRALLEQK 7.19 9.27 0.78 Serine/threonine-proteinkinase TAO1 TEGT Bax inhibitor 1 IPI:IPI00022748.4 KLMMILAMNEKDK 0.25 TFSerotransferrin IPI:IPI00022463.1 HQTVPQNTGGK 1.02 TF SerotransferrinIPI:IPI00022463.1 SDNCEDTPEAGYFAVAVVK 1.38 K TF SerotransferrinIPI:IPI00022463.1 YLGEEYVK 4.05 THBS1 Thrombospondin-1 IPI:IPI00296099.6DLASIAR 0.57 5.76 0.10 THBS1 Thrombospondin-1 IPI:IPI00296099.6FVFGTTPEDILR 1.87 1.11 1.68 THBS1 Thrombospondin-1 IPI:IPI00296099.6GTLLALERK 0.58 0.95 0.61 TIMP1 Metalloproteinase  IPI:IPI00032292.1HLACLPR 0.39 3.64 0.11 inhibitor 1 TKT Transketolase IPI:IPI00643920.2MFGIDRDAIAQAVR 0.73 TLN1 Talin-1 IPI:IPI00298994.6 ALSTDPAAPNLK 2.290.50 4.58 TLN1 Talin-1 IPI:IPI00298994.6 AVASAAAALVLK 0.91 0.36 2.56TLN1 Talin-1 IPI:IPI00298994.6 LASEAKPAAVAAENEEIGSH 0.91 IK TLN1 Talin-1IPI:IPI00298994.6 VLVQNAAGSQEK 0.64 0.29 2.24 TLN1 Talin-1IPI:IPI00298994.6 VMVTNVTSLLK 1.81 0.82 2.21 TNC Isoform 1 of TenascinIPI:IPI00031008.1 KQSEPLEITLLAPER 3.50 33.66 0.10 TPM2 Tropomyosin 2IPI:IPI00513698.1 IQLVEEELDRAQER 0.63 0.30 2.10 TTR TransthyretinIPI:IPI00022432.1 AADDTWEPFASGK 84.06 151.87 0.55 TTR TransthyretinIPI:IPI00022432.1 ADDTWEPFASGK 0.29 0.48 0.60 UBA1Ubiquitin-like modifier- IPI:IPI00645078.1 KPLLESGTLGTK 0.42activating enzyme 1 UBE2L3 Ubiquitin-conjugating IPI:IPI00021347.1TDQVIQSLIALVNDPQPEHPL 34.09 enzyme E2 L3 R VASN VasorinIPI:IPI00395488.2 YLQGSSVQLR 0.21 VCL Isoform 1 of VinculinIPI:IPI00291175.7 AQQVSQGLDVLTAK 0.81 0.38 2.14 VCLIsoform 1 of Vinculin IPI:IPI00291175.7 MSAEINEIIR 0.33 0.55 0.60 VNN1Pantetheinase IPI:IPI00030871.2 AFHYDMK 0.63 VTN VitronectinIPI:IPI00298971.1 GQYCYELDEK 0.32 VTN Vitronectin IPI:IPI00298971.1LIRDVWGIEGPIDAAFTR 0.74 VWF von Willebrand factor IPI:IPI00023014.1HIVTFDGQNFK 1.08 0.70 1.55 VWF von Willebrand factor IPI:IPI00023014.1VIVIPVGIGPHANLK 0.92 0.62 1.50 VWF von Willebrand factorIPI:IPI00023014.1 YIILLLGK 0.51 YWHAB Isoform Short of 14-3-3IPI:IPI00759832.1 YDDMAAAMK 0.25 protein beta/alpha YWHAG14-3-3 protein gamma IPI:IPI00220642.7 YDDMAAAMK 0.25

TABLE S2 Identified significant proteins Average Average Ratio HL GENE#peptides/ HL HL positive/HL SYMBOL Description protein Referencepositive negative negative A1BG Alpha-1B-glycoprotein precursor 27 IPI:IPI00022895.7 23.54 24.48 0.96 ACTA1 Actin, alpha skeletal muscle 19IPI: IPI00021428.1 3.34 6.23 0.54 ACTB Actin, cytoplasmic 1 25 IPI:IPI00021439.1 4.79 4.32 1.11 ACTN1 Alpha-actinin-1 21 IPI: IPI00013508.50.79 0.46 1.70 AGT Angiotensinogen precursor 23 IPI: IPI00032220.3 7.249.55 0.76 AHSG Alpha-2-HS-glycoprotein precursor 11 IPI: IPI00022431.127.46 16.07 1.71 AMBP AMBP protein precursor 6 IPI: IPI00022426.1 7.0315.78 0.45 ANPEP Aminopeptidase N 5 IPI: IPI00221224.6 0.59 0.74 0.80APOA4 Apolipoprotein A-IV precursor 42 IPI: IPI00304273.2 4.36 4.16 1.05APOB Apolipoprotein B-100 precursor 320 IPI: IPI00022229.1 8.33 8.670.96 APOC1 Apolipoprotein C-I precursor 6 IPI: IPI00021855.1 1.75 0.355.04 APOC2 Apolipoprotein C-II precursor 9 IPI: IPI00021856.3 4.94 2.501.97 APOC3 Apolipoprotein C-III precursor 9 IPI: IPI00021857.1 3.58 2.861.25 APOE Apolipoprotein E precursor 25 IPI: IPI00021842.1 3.79 1.832.07 APOF apolipoprotein F precursor 2 IPI: IPI00299435.3 1.38 0.36 3.85APOH Beta-2-glycoprotein 1 precursor 7 IPI: IPI00298828.3 17.52 14.911.18 APOL1 42 kDa protein 9 IPI: IPI00852826.2 0.58 0.71 0.81 APOMApolipoprotein M 3 IPI: IPI00030739.1 2.25 1.51 1.49 ARHGDIB RhoGDP-dissociation inhibitor 2 4 IPI: IPI00003817.3 0.28 2.06 0.13 ASLArgininosuccinate lyase 2 IPI: IPI00220267.7 0.36 0.58 0.62 AZGP1alpha-2-glycoprotein 1, zinc 15 IPI: IPI00166729.4 7.06 11.59 0.61 B2MBeta-2-microglobulin 5 IPI: IPI00868938.1 1.08 1.77 0.61 BCHECholinesterase precursor 13 IPI: IPI00025864.5 1.06 0.67 1.58 BLVRBFlavin reductase 2 IPI: IPI00783862.2 0.39 0.51 0.76 BTD biotinidaseprecursor 8 IPI: IPI00218413.2 0.67 0.88 0.77 C1QA Complement C1qsubcomponent subunit A 3 IPI: IPI00022392.1 1.03 1.17 0.88 precursorC1QB complement component 1, q subcomponent, 5 IPI: IPI00477992.1 0.960.66 1.47 B chain precursor C1R Complement C1r subcomponent precursor 13IPI: IPI00296165.5 1.02 0.90 1.13 C1RL Complement C1r-like protein 9IPI: IPI00009793.3 0.32 0.40 0.80 C1S Complement C1s subcomponentprecursor 18 IPI: IPI00017696.1 1.09 1.21 0.91 C2 Complement C2precursor (Fragment) 27 IPI: IPI00303963.1 1.64 1.45 1.13 C3 ComplementC3 precursor (Fragment) 216 IPI: IPI00783987.2 16.75 16.37 1.02 C4AComplement component 4A 126 IPI: IPI00643525.1 13.88 10.76 1.29 C4B C4B1128 IPI: IPI00418163.3 18.80 12.78 1.47 C4BPA C4b-binding protein alphachain precursor 9 IPI: IPI00021727.1 0.52 0.48 1.08 C5 Complement C5precursor 76 IPI: IPI00032291.2 2.48 2.95 0.84 C6 Complement component 6precursor 25 IPI: IPI00009920.2 1.08 1.29 0.84 C7 Complement componentC7 precursor 21 IPI: IPI00296608.6 1.36 1.48 0.92 C8A Complementcomponent C8 alpha chain 18 IPI: IPI00011252.1 1.72 2.91 0.59 precursorC8B Complement component C8 beta chain 18 IPI: IPI00294395.1 2.12 1.951.09 precursor C9 Complement component C9 precursor 24 IPI:IPI00022395.1 3.44 3.14 1.10 CA1 Carbonic anhydrase 1 6 IPI:IPI00215983.3 1.32 1.21 1.09 CD14 Monocyte differentiation antigen CD147 IPI: IPI00029260.2 0.39 0.27 1.46 precursor CDH5 Cadherin-5 precursor2 IPI: IPI00012792.1 0.37 0.27 1.39 CECR1 Cat eye syndrome criticalregion protein 1 2 IPI: IPI00303071.4 5.31 0.63 8.40 precursor CFBIsoform 1 of Complement factor B precursor 43 IPI: IPI00019591.1 10.499.81 1.07 (Fragment) CFD Complement factor D preproprotein 4 IPI:IPI00165972.3 0.28 1.40 0.20 CFH Isoform 1 of Complement factor Hprecursor 28 IPI: IPI00029739.5 4.04 4.34 0.93 CFI Complement factor Iprecursor 13 IPI: IPI00291867.3 2.04 2.55 0.80 CFL1 Cofilin-1 6 IPI:IPI00012011.6 0.51 0.51 1.00 CLEC3B Tetranectin precursor 6 IPI:IPI00009028.1 1.26 1.01 1.26 CNDP1 Beta-Ala-His dipeptidase precursor 21IPI: IPI00064667.4 0.44 0.44 1.00 CNTN1 Isoform 1 of Contactin-1precursor 2 IPI: IPI00029751.1 1.15 0.49 2.36 COL6A3 alpha 3 type VIcollagen isoform 1 precursor 3 IPI: IPI00022200.2 0.58 24.55 0.02 CPCeruloplasmin precursor 78 IPI: IPI00017601.1 6.40 6.07 1.05 CPB2Isoform 1 of Carboxypeptidase B2 precursor 13 IPI: IPI00329775.7 0.710.83 0.85 CPN1 Carboxypeptidase N catalytic chain 10 IPI: IPI00010295.10.54 0.65 0.83 precursor CPN2 similar to Carboxypeptidase N subunit 2 14IPI: IPI00738433.1 1.43 1.60 0.89 precursor CRP Isoform 1 of C-reactiveprotein precursor 9 IPI: IPI00022389.1 15.24 3.24 4.71 CST3 Cystatin-Cprecursor 3 IPI: IPI00032293.1 1.64 1.04 1.57 ECM1 Extracellular matrixprotein 1 10 IPI: IPI00645849.1 0.36 0.38 0.93 EFEMP1 Isoform 1 ofEGF-containing fibulin-like 4 IPI: IPI00029658.1 0.21 0.41 0.53extracellular matrix protein 1 precursor F10 Coagulation factor Xprecursor 9 IPI: IPI00019576.1 0.82 1.19 0.69 F11 Isoform 1 ofCoagulation factor XI 8 IPI: IPI00008556.1 0.24 0.26 0.93 precursor F2Prothrombin precursor (Fragment) 20 IPI: IPI00019568.1 6.98 6.10 1.14 F5Coagulation factor V 14 IPI: IPI00022937.4 0.42 0.34 1.26 FCGBPIgGFc-binding protein precursor 4 IPI: IPI00242956.4 1.88 1.55 1.21 FCN3Isoform 1 of Ficolin-3 precursor 9 IPI: IPI00293925.2 3.78 4.00 0.94 FGAIsoform 1 of Fibrinogen alpha chain 41 IPI: IPI00021885.1 2.55 0.96 2.65precursor FLNA filamin A, alpha isoform 1 48 IPI: IPI00302592.2 0.510.42 1.22 FN1 Isoform 1 of Fibronectin precursor 19 IPI: IPI00022418.10.37 0.40 0.93 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 7 IPI:IPI00219018.7 0.93 1.06 0.88 GC Vitamin D-binding protein precursor 32IPI: IPI00555812.4 13.45 10.90 1.23 GGH Gamma-glutamyl hydrolaseprecursor 4 IPI: IPI00023728.1 5.74 4.71 1.22 GP1BA plateletglycoprotein Ib alpha polypeptide 5 IPI: IPI00748955.2 0.52 0.67 0.78precursor GPLD1 Isoform 1 of Phosphatidylinositol-glycan- 11 IPI:IPI00299503.2 2.04 0.35 5.77 specific phospholipase D precursor GSNIsoform 1 of Gelsolin precursor 44 IPI: IPI00026314.1 1.64 2.84 0.58HBA2 Hemoglobin subunit alpha 9 IPI: IPI00410714.5 4.71 4.25 1.11 HGFACHepatocyte growth factor activator precursor 5 IPI: IPI00029193.1 0.420.42 1.01 HPR Isoform 1 of Haptoglobin-related protein 15 IPI:IPI00477597.1 1.73 1.72 1.01 precursor HPX Hemopexin precursor 39 IPI:IPI00022488.1 12.50 13.53 0.92 HRG Histidine-rich glycoprotein precursor21 IPI: IPI00022371.1 7.89 9.94 0.79 HSPA8 Heat shock 70 kDa protein 8isoform 2 7 IPI: IPI00795040.1 0.50 0.52 0.98 variant (Fragment) ICAM1Intercellular adhesion molecule 1 precursor 3 IPI: IPI00008494.4 0.800.62 1.28 IGFALS Insulin-like growth factor-binding protein 20 IPI:IPI00020996.3 1.01 1.12 0.90 complex acid labile chain precursor IGFBP2Insulin-like growth factor-binding protein 2 2 IPI: IPI00297284.1 0.280.17 1.68 precursor IGFBP6 Insulin-like growth factor-binding protein 62 IPI: IPI00029235.1 0.26 0.25 1.04 precursor ITIH1 Inter-alpha-trypsininhibitor heavy chain H1 38 IPI: IPI00292530.1 4.28 5.84 0.73 precursorITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 62 IPI: IPI00305461.25.39 7.95 0.68 precursor ITIH3 Isoform 1 of Inter-alpha-trypsininhibitor 28 IPI: IPI00028413.8 1.91 2.41 0.79 heavy chain H3 precursorITIH4 Isoform 1 of Inter-alpha-trypsin inhibitor 53 IPI: IPI00294193.48.60 8.89 0.97 heavy chain H4 precursor KLKB1 Plasma kallikreinprecursor 16 IPI: IPI00654888.4 1.73 1.99 0.87 KNG1 Kininogen-1 16 IPI:IPI00032328.2 17.24 21.46 0.80 KRT10 Keratin, type I cytoskeletal 10 9IPI: IPI00009865.2 1.72 2.67 0.64 KRT2 Keratin, type II cytoskeletal 2epidermal 4 IPI: IPI00021304.1 2.87 1.05 2.74 LBPLipopolysaccharide-binding protein 8 IPI: IPI00032311.4 0.54 0.42 1.29precursor LCP1 Plastin-2 7 IPI: IPI00010471.5 0.31 0.25 1.24 LDHBL-lactate dehydrogenase B chain 9 IPI: IPI00219217.3 1.92 0.92 2.08 LPAApolipoprotein 11 IPI: IPI00029168.1 0.44 0.61 0.72 LRG1 Leucine-richalpha-2-glycoprotein precursor 12 IPI: IPI00022417.4 15.44 11.60 1.33LUM Lumican precursor 11 IPI: IPI00020986.2 1.82 4.43 0.41 MASP1mannan-binding lectin serine protease 1 5 IPI: IPI00290283.6 0.25 0.430.57 isoform 2 precursor MBL2 Mannose-binding protein C precursor 5 IPI:IPI00004373.1 1.26 0.43 2.97 MCAM Isoform 1 of Cell surface glycoprotein2 IPI: IPI00016334.2 2.49 1.39 1.79 MUC18 precursor MSN Moesin 4 IPI:IPI00219365.3 1.90 0.62 3.07 MTMR15 Isoform 1 of Coiled-coildomain-containing 2 IPI: IPI00007317.4 9.30 8.88 1.05 protein MTMR15PCYOX1 Prenylcysteine oxidase 1 precursor 2 IPI: IPI00384280.5 0.19 0.210.90 PDIA3 Protein disulfide-isomerase A3 precursor 4 IPI: IPI00025252.10.27 0.40 0.68 PFN1 Profilin-1 9 IPI: IPI00216691.5 1.12 1.38 0.81PGLYRP2 Isoform 1 of N-acetylmuramoyl-L-alanine 12 IPI: IPI00163207.11.19 2.02 0.59 amidase precursor PI16 Isoform 1 of Peptidase inhibitor16 3 IPI: IPI00301143.5 0.60 0.41 1.48 precursor PLEK Pleckstrin 5 IPI:IPI00306311.8 0.53 0.52 1.01 PNP Purine nucleoside phosphorylase 2 IPI:IPI00871140.1 1.80 3.37 0.53 PPBP Platelet basic protein precursor 5IPI: IPI00022445.1 0.62 0.38 1.63 PRDX2 Peroxiredoxin-2 4 IPI:IPI00027350.3 0.54 0.71 0.77 PROZ Isoform 1 of Vitamin K-dependentprotein Z 3 IPI: IPI00027843.1 0.23 0.30 0.76 precursor PTGDSProstaglandin-H2 D-isomerase precursor 3 IPI: IPI00013179.1 0.28 4.340.06 PVR Isoform Beta of Poliovirus receptor 2 IPI: IPI00219425.3 0.090.15 0.56 precursor PZP Pregnancy zone protein precursor 12 IPI:IPI00025426.2 0.55 0.26 2.15 QSOX1 Isoform 1 of Sulfhydryl oxidase 1precursor 2 IPI: IPI00003590.2 0.37 0.12 3.13 RBP4 Plasmaretinol-binding protein precursor 10 IPI: IPI00022420.3 8.57 6.59 1.30RELN reelin isoform a 2 IPI: IPI00241562.4 0.84 0.88 0.94 SAA1 serumamyloid A2 7 IPI: IPI00006146.4 1.45 0.51 2.86 SAA2 Serum amyloid Aprotein precursor 8 IPI: IPI00552578.2 3.84 2.19 1.75 SAA4 Serum amyloidA-4 protein precursor 8 IPI: IPI00019399.1 1.20 0.93 1.29 SELENBP1Selenium-binding protein 1 2 IPI: IPI00012303.2 11.85 20.47 0.58 SEMA7ASemaphorin-7A precursor 2 IPI: IPI00025257.1 2.02 1.15 1.76 SEPP1Selenoprotein P precursor 3 IPI: IPI00029061.2 0.56 0.83 0.67 SERPINA10Protein Z-dependent protease inhibitor 9 IPI: IPI00007199.4 0.33 0.291.14 precursor SERPINA3 Alpha-1-antichymotrypsin precursor 50 IPI:IPI00550991.3 18.18 16.80 1.08 SERPINA4 Kallistatin precursor 19 IPI:IPI00328609.3 1.09 1.50 0.73 SERPINA7 Thyroxine-binding globulinprecursor 20 IPI: IPI00292946.1 2.09 1.89 1.11 SERPINC1 Antithrombin IIIvariant 49 IPI: IPI00032179.2 7.26 7.87 0.92 SERPINC1 SERPINC1 protein27 IPI: IPI00844156.2 4.65 4.06 1.14 SERPIND1 Serpin peptidaseinhibitor, clade D (Heparin 22 IPI: IPI00292950.4 5.63 5.30 1.06cofactor), member 1 SERPINF1 Pigment epithelium-derived factor precursor27 IPI: IPI00006114.4 2.07 2.83 0.73 SERPINF2 Alpha-2-antiplasminprecursor 24 IPI: IPI00879231.1 6.34 6.17 1.03 SERPING1 Plasma proteaseC1 inhibitor precursor 42 IPI: IPI00291866.5 7.43 10.58 0.70 SHBGIsoform 1 of Sex hormone-binding globulin 10 IPI: IPI00023019.1 0.330.42 0.78 precursor TAGLN2 Transgelin-2 6 IPI: IPI00550363.3 0.42 0.311.36 THBS1 Thrombospondin-1 precursor 18 IPI: IPI00296099.6 0.49 0.371.31 TIMP1 Metalloproteinase inhibitor 1 precursor 2 IPI: IPI00032292.10.74 3.51 0.21 TLN1 Talin-1 40 IPI: IPI00298994.6 0.83 0.39 2.15 TNCIsoform 1 of Tenascin precursor 3 IPI: IPI00031008.1 0.91 0.94 0.97 TPM2Tropomyosin 2 4 IPI: IPI00513698.1 0.37 0.32 1.17 TTR Transthyretinprecursor 19 IPI: IPI00022432.1 6.96 9.74 0.71 VASN Vasorin precursor 3IPI: IPI00395488.2 0.25 0.32 0.77 VCL Isoform 1 of Vinculin 20 IPI:IPI00291175.7 0.35 0.25 1.40 VTN Vitronectin precursor 15 IPI:IPI00298971.1 9.92 10.69 0.93 VWF von Willebrand factor precursor 25IPI: IPI00023014.1 1.34 1.09 1.22 YWHAB Isoform Short of 14-3-3 proteinbeta/alpha 4 IPI: IPI00759832.1 0.28 0.23 1.22 YWHAG 14-3-3 proteingamma 4 IPI: IPI00220642.7 0.37 0.63 0.59

TABLE S3 Significantly altered proteins and related biologicalfunctions. Peptides were initially identified by mass spectrometry.Selected biological functions and expression sites associated with theindividual proteins were identified by Ingenuity Pathway Analysis (IPA).Gene #pept/ Biological Expressed^(b) in Protein Symbol protein Ratio^(a)Function Liver WBC^(c) 14-3-3 protein gamma YWHAG 4 0.59 Cancer X Actin,alpha skeletal muscle ACTA1 19 0.54 X X Alpha 3 type VI collagen COL6A33 0.02 Cancer X X Alpha-2-glycoprotein 1, AZGP1 15 0.61 Cancer zincAlpha-2-HS-glycoprotein AHSG 11 1.71 IR^(d), Cancer X Alpha-actinin-1ACTN1 21 1.70 X AMBP protein AMBP 6 0.45 IR, Cancer X Apolipoprotein LPA11 0.70 Apolipoprotein C-I APOC1 6 5.04 Cancer X X Apolipoprotein C-IIAPOC2 9 1.97 Apolipoprotein E APOE 25 2.07 IR, Cancer X apolipoprotein FAPOF 2 3.85 Cancer X Apolipoprotein M APOM 3 1.50 X Argininosuccinatelyase ASL 2 0.62 X Beta-2-microglobulin B2M 5 0.61 IR, Cancer X X C4B1C4B 128 1.50 IR, Cancer X Cat eye syndrome critical CECR1 2 8.40 regionprotein 1 Cell surface glycoprotein MCAM 2 1.79 IR, Cancer MUC18Cholinesterase BCHE 13 1.58 Coagulation factor X F10 9 0.69 X Complementcomponent 4A C4A 126 1.29 IR, Cancer X Complement component C8 C8A 180.59 IR X alpha chain Complement factor D CFD 4 0.20 IR, Cancer Xpreproprotein Contactin-1 CNTN1 2 2.36 C-reactive protein CRP 9 4.71 IR,Cancer X Cystatin-C CST3 3 1.57 Cancer X EGF-containing fibulin-likeEFEMP1 4 0.53 Cancer X extracellular matrix protein 1 Gelsolin GSN 440.58 IR, Cancer Insulin-like growth factor- IGFBP2 2 1.68 Cancer X Xbinding protein 2 Inter-alpha-trypsin inhibitor ITIH1 38 0.70 X heavychain H1 Inter-alpha-trypsin inhibitor ITIH2 62 0.70 X heavy chain H2Phosphatidylinositol- GPLD1 11 5.77 X glycan-specific phospholipase DSulfhydryl oxidase 1 QSOX1 2 3.13 X Kallistatin SERPINA4 19 0.70Keratin, type I cytoskeletal KRT10 9 0.64 X X 10 Keratin, type IIcytoskeletal KRT2 4 2.74 2 epidermal L-lactate dehydrogenase B LDHB 92.08 X chain Lumican LUM 11 0.41 IR X Mannan-binding lectin MASP1 5 0.57IR, Cancer X serine protease 1 Mannose-binding protein C MBL2 5 2.97 IRMetalloproteinase inhibitor 1 TIMP1 2 0.21 IR, Cancer X X Moesin MSN 43.07 IR X Monocyte differentiation CD14 7 1.5 IR, Cancer X antigen CD14Peptidase inhibitor 16 PI16 3 1.50 X Pigment epithelium-derived SERPINF127 0.70 X factor Plasma protease C1 SERPING1 42 0.70 X X inhibitorPlatelet basic protein PPBP 5 1.63 IR X Poliovirus receptor PVR 2 0.56IR X Pregnancy zone protein PZP 12 2.15 Prostaglandin-H2 D- PTGDS 3 0.06IR, Cancer X isomerase Protein disulfide-isomerase PDIA3 4 0.68 X A3Purine nucleoside PNP 2 0.53 IR, Cancer X phosphorylase RhoGDP-dissociation ARHGDIB 4 0.13 IR, Cancer X X inhibitor 2Selenium-binding protein 1 SELENBP1 2 0.58 Cancer Selenoprotein P SEPP13 0.70 X X Semaphorin-7A/CD108 SEMA7A 2 1.76 IR X Serum amyloid A SAA2 81.75 X X Serum amyloid A2 SAA1 7 2.86 IR, Cancer X X Talin-1 TLN1 402.15 X Transthyretin TTR 19 0.70 X ^(a)Ratio of the proteinconcentrations from HIV-infected patients with HL versus HIV-infectedpatients without HL. ^(b)An “X” indicates that IPA lists these tissuesor cell types as a known source of these proteins. There are commonlyother tissues or cellular sources for these proteins that are notincluded in this table. ^(c)WBC, white blood cells. ^(d)IR, inflammatoryresponse.

We claim:
 1. A method consisting of: measuring the level of all proteinslisted in Table S3 in a plasma sample from a person; and comparing thelevel of the proteins in the plasma sample with the level of theproteins in a normal or healthy subject.
 2. The method of claim 1,wherein the person has lymphoma.
 3. The method of claim 1, wherein theperson has Hodgkin's lymphoma or non-Hodgkin's lymphoma.
 4. The methodof claim 1, wherein the measuring comprises contacting the plasma samplewith a reagent that reacts with proteins in the plasma sample to detectthe presence of the proteins listed in Table S3.
 5. The method of claim4, wherein the reagent is an antibody.
 6. The method of claim 3, whereinthe person is infected with human immunodeficiency virus (HIV).
 7. Themethod of claim 1, wherein measuring the level of all proteins listed inTable S3 comprises analyzing the plasma sample with mass spectrometry.8. The method of claim 1, wherein comparing the level of the proteins inthe plasma sample to the normal or healthy subject comprises determiningif the level of all of the proteins listed in Table S3 in the plasmasample differ by at least 1.5 fold in comparison to the level of all ofthe proteins listed in Table S3 in the normal or healthy subject.